|
G |
Chaf1b |
chromatin assembly factor 1 subunit B |
|
ISO |
protein:increased expression:: |
RGD |
PMID:22882088 |
RGD:9587477 |
NCBI chrNW_004936500:6,262,207...6,288,833
Ensembl chrNW_004936500:6,262,229...6,288,839
|
|
G |
Erg |
ETS transcription factor ERG |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27783944 |
|
NCBI chrNW_004936500:4,459,298...4,623,290
Ensembl chrNW_004936500:4,459,275...4,624,432
|
|
G |
Etv1 |
ETS variant transcription factor 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27783944 |
|
NCBI chrNW_004936546:742,586...832,972
Ensembl chrNW_004936546:740,485...833,082
|
|
G |
Etv4 |
ETS variant transcription factor 4 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27783944 |
|
NCBI chrNW_004936541:120,533...138,463
Ensembl chrNW_004936541:123,049...139,256
|
|
G |
Etv5 |
ETS variant transcription factor 5 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27783944 |
|
NCBI chrNW_004936578:3,795,000...3,854,269
Ensembl chrNW_004936578:3,794,982...3,854,140
|
|
G |
Ewsr1 |
EWS RNA binding protein 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27783944 |
|
NCBI chrNW_004936657:3,296,217...3,323,473
|
|
G |
Hdlbp |
high density lipoprotein binding protein |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:25129143 |
|
NCBI chrNW_004936745:555,020...608,572
Ensembl chrNW_004936745:555,710...607,135
|
|
G |
Hoxd9 |
homeobox D9 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26075790 |
|
NCBI chrNW_004936509:5,609,744...5,611,943
Ensembl chrNW_004936509:5,609,744...5,611,943
|
|
G |
Hras |
HRas proto-oncogene, GTPase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:12082015 |
|
NCBI chrNW_004936888:375,372...378,125
Ensembl chrNW_004936888:375,377...377,958
|
|
|
G |
Ca9 |
carbonic anhydrase 9 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19808899 |
|
NCBI chrNW_004936524:3,672,393...3,678,630
Ensembl chrNW_004936524:3,672,541...3,678,433
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19808899 |
|
NCBI chrNW_004936495:5,770,988...5,816,157
Ensembl chrNW_004936495:5,770,669...5,816,157
|
|
|
G |
Aicda |
activation induced cytidine deaminase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21570118 |
|
NCBI chrNW_004936870:25,039...34,601
Ensembl chrNW_004936870:25,039...34,601
|
|
G |
Bcr |
BCR activator of RhoGEF and GTPase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21570118 |
|
NCBI chrNW_004936619:288,377...432,297
Ensembl chrNW_004936619:288,340...432,315
|
|
G |
Esr2 |
estrogen receptor 2 |
|
ISO |
|
RGD |
PMID:12740446 |
RGD:734951 |
NCBI chrNW_004936495:7,956,168...8,018,356
Ensembl chrNW_004936495:7,956,766...8,004,357
|
|
G |
Hmox1 |
heme oxygenase 1 |
|
ISO |
|
RGD |
PMID:22139798 |
RGD:10755566 |
NCBI chrNW_004936492:5,042,353...5,049,216
Ensembl chrNW_004936492:5,042,330...5,049,311
|
|
G |
Tcn2 |
transcobalamin 2 |
|
ISO |
protein:increased expression:: |
RGD |
PMID:1059479 |
RGD:11060122 |
NCBI chrNW_004936904:97,535...113,886
Ensembl chrNW_004936904:95,542...113,985
|
|
|
G |
Brip1 |
BRCA1 interacting DNA helicase 1 |
|
ISO |
associated with Breast Neoplasms; human gene in a mouse model |
RGD |
PMID:22875853 |
RGD:11252149 |
NCBI chrNW_004936490:3,001,445...3,139,538
Ensembl chrNW_004936490:3,003,484...3,137,479
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
disease_progression |
ISO |
associated with hepatocellular carcinoma;protein:increased expression:liver (human) |
RGD |
PMID:19508713 |
RGD:152023653 |
NCBI chrNW_004936469:39,794,613...39,798,448
Ensembl chrNW_004936469:39,794,584...39,798,459
|
|
G |
Enpp1 |
ectonucleotide pyrophosphatase/phosphodiesterase 1 |
|
ISO |
associated with Breast Neoplasms;mRNA:increased expression:bone element (human) |
RGD |
PMID:23861746 |
RGD:13204736 |
NCBI chrNW_004937067:194,375...246,607
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
|
ISO |
associated with Carcinoma, Renal Cell; mRNA, protein:increased expression:bone (human) |
RGD |
PMID:18709334 |
RGD:2306080 |
NCBI chrNW_004936551:5,040,084...5,050,384
Ensembl chrNW_004936551:5,040,084...5,050,384
|
|
G |
Pdgfd |
platelet derived growth factor D |
|
ISO |
associated with prostate carcinoma |
RGD |
PMID:22158043 |
RGD:13506772 |
NCBI chrNW_004936551:3,974,140...4,197,852
Ensembl chrNW_004936551:3,974,104...4,198,927
|
|
|
G |
Abl1 |
ABL proto-oncogene 1, non-receptor tyrosine kinase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:23968727 |
|
NCBI chrNW_004936487:17,690,206...17,819,619
Ensembl chrNW_004936487:17,690,968...17,819,669
|
|
G |
Adprh |
ADP-ribosylarginine hydrolase |
|
ISO |
|
RGD |
PMID:21697277 |
RGD:13838723 |
NCBI chrNW_004936536:6,499,316...6,508,311
Ensembl chrNW_004936536:6,499,256...6,508,752
|
|
G |
Akr1a1 |
aldo-keto reductase family 1 member A1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:32805337 |
|
NCBI chrNW_004936474:26,680,736...26,696,996
Ensembl chrNW_004936474:26,680,676...26,697,214
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:32045588 |
|
NCBI chrNW_004936621:620,163...639,115
Ensembl chrNW_004936621:620,074...639,093
|
|
G |
Braf |
B-Raf proto-oncogene, serine/threonine kinase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:24717435 |
|
NCBI chrNW_004936592:4,728,371...4,833,830
Ensembl chrNW_004936592:4,737,011...4,834,664
|
|
G |
Cav1 |
caveolin 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:29247004 |
|
NCBI chrNW_004936589:2,504,235...2,536,778
Ensembl chrNW_004936589:2,504,224...2,537,170
|
|
G |
Cux1 |
cut like homeobox 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:24316979 |
|
NCBI chrNW_004936543:1,482,606...1,781,294
Ensembl chrNW_004936543:1,485,970...1,796,070
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
disease_progression |
ISO |
|
RGD |
PMID:21163286 |
RGD:9588222 |
NCBI chrNW_004936659:520,181...565,496
Ensembl chrNW_004936659:520,493...565,416
|
|
G |
Dnmt3a |
DNA methyltransferase 3 alpha |
disease_progression |
ISO |
|
RGD |
PMID:21163286 |
RGD:9588222 |
NCBI chrNW_004936493:6,963,406...7,013,256
Ensembl chrNW_004936493:6,935,386...7,007,610
|
|
G |
Epas1 |
endothelial PAS domain protein 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26735578 |
|
NCBI chrNW_004936508:5,855,748...5,938,879
Ensembl chrNW_004936508:5,855,732...5,938,856
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:25221644 |
|
NCBI chrNW_004936490:14,887,062...14,910,038
Ensembl chrNW_004936490:14,887,043...14,909,956
|
|
G |
Gata3 |
GATA binding protein 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:35115686 |
|
NCBI chrNW_004936484:6,780,692...6,800,883
Ensembl chrNW_004936484:6,780,692...6,800,966
|
|
G |
Isg15 |
ISG15 ubiquitin like modifier |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:35506701 |
|
NCBI chrNW_004936737:2,043,383...2,044,761
|
|
G |
Kras |
KRAS proto-oncogene, GTPase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26595770 PMID:29247004 |
|
NCBI chrNW_004936548:2,078,568...2,113,877
Ensembl chrNW_004936548:2,079,036...2,110,523
|
|
G |
Map3k8 |
mitogen-activated protein kinase kinase kinase 8 |
|
ISO |
|
RGD |
PMID:15287022 PMID:23533274 |
RGD:151356924 RGD:151356978 |
NCBI chrNW_004936613:3,791,684...3,813,857
Ensembl chrNW_004936613:3,791,681...3,813,892
|
|
G |
Met |
MET proto-oncogene, receptor tyrosine kinase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:32045588 |
|
NCBI chrNW_004936589:2,280,803...2,390,179
Ensembl chrNW_004936589:2,280,799...2,390,179
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:29228771 |
|
NCBI chrNW_004936509:6,589,967...6,621,171
Ensembl chrNW_004936509:6,590,630...6,620,262
|
|
G |
Pafah1b1 |
platelet activating factor acetylhydrolase 1b regulatory subunit 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:24487275 |
|
NCBI chrNW_004936538:8,612,142...8,693,698
Ensembl chrNW_004936538:8,612,049...8,694,015
|
|
G |
Pou5f1 |
POU class 5 homeobox 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:35506701 |
|
NCBI chrNW_004936837:827,568...838,933
|
|
G |
Sparc |
secreted protein acidic and cysteine rich |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26783756 |
|
NCBI chrNW_004936515:11,026,156...11,046,812
Ensembl chrNW_004936515:11,025,724...11,046,849
|
|
G |
Tnfsf8 |
TNF superfamily member 8 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:11552987 |
|
NCBI chrNW_004936487:4,057,637...4,081,207
Ensembl chrNW_004936487:4,057,643...4,081,207
|
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:29044505 |
|
NCBI chrNW_004936490:14,887,062...14,910,038
Ensembl chrNW_004936490:14,887,043...14,909,956
|
|
|
G |
Braf |
B-Raf proto-oncogene, serine/threonine kinase |
severity |
ISO |
associated with colorectal cancer;DNA:missense mutation:cds:p.V600E (human) associated with colorectal cancer;DNA:mutation:cds: associated with skin melanoma;DNA:missense mutations:cds: associated with colorectal cancer;DNA:missense mutations:cds:pV599E,p.V600E (human) associated with colorectal cancer;DNA:mutations:multiple |
RGD |
PMID:22331825 PMID:23010994 PMID:26775732 PMID:27737491 PMID:28787433 |
RGD:11554843 RGD:14696791 RGD:15039394 RGD:18337264 RGD:18337265 |
NCBI chrNW_004936592:4,728,371...4,833,830
Ensembl chrNW_004936592:4,737,011...4,834,664
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
treatment |
ISO |
associated with Animal Mammary Neoplasms; |
RGD |
PMID:15692764 |
RGD:14995455 |
NCBI chrNW_004936490:253,279...259,947
Ensembl chrNW_004936490:253,034...259,965
|
|
G |
Ccnd2 |
cyclin D2 |
|
ISO |
associated with colorectal cancer;protein:increased expression:colorectum |
RGD |
PMID:19508551 |
RGD:151665111 |
NCBI chrNW_004936606:4,474,801...4,496,158
Ensembl chrNW_004936606:4,474,749...4,496,810
|
|
G |
Ccng1 |
cyclin G1 |
treatment |
ISO |
human cells in mouse model |
RGD |
PMID:10910035 |
RGD:151356987 |
NCBI chrNW_004936515:614,287...621,213
Ensembl chrNW_004936515:614,290...619,963
|
|
G |
Cd44 |
CD44 molecule (IN blood group) |
|
ISO |
associated with Breast Neoplasm;protein:increased expression:liver |
RGD |
PMID:17991717 |
RGD:2289349 |
NCBI chrNW_004936533:2,949,026...3,033,166
|
|
G |
Chd4 |
chromodomain helicase DNA binding protein 4 |
ameliorates |
ISO |
associated with human colon adenocarcinoma cells in a mouse model |
RGD |
PMID:28486105 |
RGD:153323299 |
NCBI chrNW_004936709:1,183,243...1,214,144
Ensembl chrNW_004936709:1,183,254...1,214,149
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
treatment |
ISO |
associated with colon carcinoma; |
RGD |
PMID:30381616 |
RGD:27095891 |
NCBI chrNW_004936676:60,869...63,028
Ensembl chrNW_004936676:60,621...63,106
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
ameliorates |
ISO |
associated with colorectal cancer; human cells in mouse model |
RGD |
PMID:30789971 |
RGD:151893289 |
NCBI chrNW_004936617:4,224,131...4,239,080
Ensembl chrNW_004936617:4,224,131...4,238,796
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
ameliorates |
ISO |
associated with colorectal cancer; human cells in mouse model human cells in mouse model; associated with colorectal cancer |
RGD |
PMID:29436696 PMID:30789971 |
RGD:151893289 RGD:152023643 |
NCBI chrNW_004936469:39,794,613...39,798,448
Ensembl chrNW_004936469:39,794,584...39,798,459
|
|
G |
Daxx |
death domain associated protein |
exacerbates |
ISO |
associated with colon cancer; mRNA:decreased expression:liver (human) associated with neuroendocrine tumor;DNA:mutations:CDS:multiple (human) associated with pancreatic endocrine carcinoma;DNA:mutations:CDS:multiple (human) |
RGD |
PMID:30339629 PMID:30342802 PMID:31942198 |
RGD:152025194 RGD:152025199 RGD:152025203 |
NCBI chrNW_004936476:25,546,091...25,550,390
Ensembl chrNW_004936476:25,546,036...25,550,392
|
|
G |
Ddr1 |
discoidin domain receptor tyrosine kinase 1 |
treatment |
ISO |
mRNA:increased expression:liver (mouse) human cells in mouse model; nilotinib |
RGD |
PMID:29438985 PMID:30666650 PMID:33110221 |
RGD:151347537 RGD:151347685 RGD:151347840 |
NCBI chrNW_004936837:523,227...538,799
Ensembl chrNW_004936837:523,266...538,833
|
|
G |
Ddr2 |
discoidin domain receptor tyrosine kinase 2 |
ameliorates |
ISO |
associated with colon carcinoma associated with melanoma; |
RGD |
PMID:21701781 PMID:22071959 |
RGD:150429701 RGD:150429713 |
NCBI chrNW_004936831:799,948...946,139
Ensembl chrNW_004936831:865,965...946,139
|
|
G |
Dock6 |
dedicator of cytokinesis 6 |
ameliorates |
ISO |
associated with stomach cancer; |
RGD |
PMID:29587866 |
RGD:155791564 |
NCBI chrNW_004936659:1,341,144...1,394,484
Ensembl chrNW_004936659:1,341,331...1,379,728
|
|
G |
Fbxw7 |
F-box and WD repeat domain containing 7 |
disease_progression |
ISO |
associated with colorectal cancer; |
RGD |
PMID:28846828 |
RGD:21408566 |
NCBI chrNW_004936689:2,261,163...2,449,951
Ensembl chrNW_004936689:2,259,477...2,344,764
|
|
G |
Fgfr1 |
fibroblast growth factor receptor 1 |
|
ISO |
associated with colorectal cancer;mRNA:increased expression:colorectal mucosa: |
RGD |
PMID:19082464 |
RGD:25330357 |
NCBI chrNW_004936710:1,760,365...1,815,269
Ensembl chrNW_004936710:1,760,089...1,815,508
|
|
G |
Fosl2 |
FOS like 2, AP-1 transcription factor subunit |
|
ISO |
human cells in mouse model |
RGD |
PMID:30114390 |
RGD:153344554 |
NCBI chrNW_004936493:4,308,683...4,327,102
Ensembl chrNW_004936493:4,304,395...4,327,179
|
|
G |
Gpc3 |
glypican 3 |
|
ISO |
protein:increased expression:blood serum (human) |
RGD |
PMID:28801286 |
RGD:243065135 |
NCBI chrNW_004936691:1,060,013...1,459,736
Ensembl chrNW_004936691:1,059,994...1,459,740
|
|
G |
Hmbs |
hydroxymethylbilane synthase |
|
ISO |
associated with colon adenocarcinoma;protein:decreased activity:liver(rat) |
RGD |
PMID:1386052 |
RGD:25440496 |
NCBI chrNW_004936542:4,037,888...4,046,089
Ensembl chrNW_004936542:4,037,201...4,050,810
|
|
G |
Il2 |
interleukin 2 |
treatment |
ISO |
associated with Colorectal Neoplasms, Carcinoma, Hepatocellular; associated with colon carcinoma |
RGD |
PMID:9354462 PMID:11591892 |
RGD:14928215 RGD:8663446 |
NCBI chrNW_004936662:1,594,953...1,599,625
Ensembl chrNW_004936662:1,594,953...1,599,625
|
|
G |
Iqsec1 |
IQ motif and Sec7 domain ArfGEF 1 |
|
ISO |
human cells in mouse model |
RGD |
PMID:22662237 |
RGD:153344589 |
NCBI chrNW_004936898:318,564...425,785
Ensembl chrNW_004936898:337,400...425,859
|
|
G |
LOC101964975 |
interleukin-8 |
|
ISO |
associated with colorectal cancer; human colon adenocarcinoma cells in a mouse model |
RGD |
PMID:29679563 |
RGD:26884358 |
NCBI chrNW_004936598:1,779,471...1,781,353
Ensembl chrNW_004936598:1,779,471...1,781,353
|
|
G |
LOC101968921 |
angiotensin-converting enzyme |
|
ISO |
associated with colorectal cancer;mRNA:increased expression:liver (mouse) |
RGD |
PMID:20380732 |
RGD:25671446 |
NCBI chrNW_004936541:4,157,847...4,178,156
Ensembl chrNW_004936541:4,157,393...4,178,177
|
|
G |
Map2k7 |
mitogen-activated protein kinase kinase 7 |
|
ISO |
associated with colon cancer;protein:increased expression:colon (human) |
RGD |
PMID:24533778 |
RGD:155259116 |
NCBI chrNW_004936588:4,882,191...4,891,807
Ensembl chrNW_004936588:4,882,184...4,892,071
|
|
G |
Mpl |
MPL proto-oncogene, thrombopoietin receptor |
exacerbates severity |
ISO |
associated with pancreatic cancer; protein:increased expression:liver, pancreas (human) associated with colorectal carcinoma;protein:increased expression:colorectum (human) associated with pancreatic ductal adenocarcinoma; human cells in mouse model |
RGD |
PMID:23747337 PMID:30770989 |
RGD:126925751 RGD:126925752 |
NCBI chrNW_004936474:24,744,673...24,757,189
Ensembl chrNW_004936474:24,744,673...24,757,085
|
|
G |
Nras |
NRAS proto-oncogene, GTPase |
susceptibility |
ISO |
human gene in a mouse model;DNA:missense mutations:cds:p.G12V, p.Q61K (human) associated with colorectal cancer;DNA:mutations:exons (human) associated with melanoma;DNA:mutations: exons (human) |
RGD |
PMID:26799184 PMID:28011498 PMID:28787433 |
RGD:14696774 RGD:14696791 RGD:14696792 |
NCBI chrNW_004936627:73,413...82,590
Ensembl chrNW_004936627:73,413...82,590
|
|
G |
Ptprb |
protein tyrosine phosphatase receptor type B |
treatment |
ISO |
mouse tumor cells in mouse recipient |
RGD |
PMID:31348125 |
RGD:151660353 |
NCBI chrNW_004936545:8,150,766...8,235,674
Ensembl chrNW_004936545:8,147,291...8,235,715
|
|
G |
Rictor |
RPTOR independent companion of MTOR complex 2 |
disease_progression |
ISO |
mRNA:increased expression:liver (human) |
RGD |
PMID:30404068 |
RGD:152995463 |
NCBI chrNW_004936518:3,198,312...3,314,393
Ensembl chrNW_004936518:3,198,337...3,310,000
|
|
G |
Rnf43 |
ring finger protein 43 |
|
ISO |
associated with colorectal adenocarcinoma;mRNA:increased expression:liver (human) |
RGD |
PMID:28789449 |
RGD:151361221 |
NCBI chrNW_004936490:4,660,904...4,742,669
Ensembl chrNW_004936490:4,683,725...4,741,828
|
|
G |
Slc3a2 |
solute carrier family 3 member 2 |
severity |
ISO |
associated with colon adenocarcinoma |
RGD |
PMID:11745822 |
RGD:151361130 |
NCBI chrNW_004936581:424,801...441,592
|
|
G |
Slc7a5 |
solute carrier family 7 member 5 |
severity |
ISO |
associated with colon adenocarcinoma associated with colon cancer |
RGD |
PMID:11718450 PMID:11745822 |
RGD:151361129 RGD:151361130 |
NCBI chrNW_004936641:1,513,110...1,538,955
|
|
G |
Smad4 |
SMAD family member 4 |
treatment |
ISO |
associated with colorectal carcinoma;protein:decreased expression:colorectum: associated with colorectal carcinoma; DNA:mutations: : |
RGD |
PMID:17390050 PMID:29551247 |
RGD:18937000 RGD:21066338 |
NCBI chrNW_004936497:12,242,869...12,278,012
Ensembl chrNW_004936497:12,249,140...12,278,123
|
|
G |
Sox30 |
SRY-box transcription factor 30 |
ameliorates |
ISO |
|
RGD |
PMID:29739711 |
RGD:151660333 |
NCBI chrNW_004936515:5,501,315...5,537,946
Ensembl chrNW_004936515:5,458,393...5,537,946
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
disease_progression |
ISO |
associated with colon cancer;protein:increased activity:colon |
RGD |
PMID:7678609 |
RGD:150521542 |
NCBI chrNW_004936561:3,826,802...3,844,406
Ensembl chrNW_004936561:3,825,787...3,844,483
|
|
G |
Vegfa |
vascular endothelial growth factor A |
|
ISO |
associated with colorectal carcinoma;mRNA,protein:increased expression:liver: |
RGD |
PMID:22156924 |
RGD:15014782 |
NCBI chrNW_004936476:16,245,134...16,261,180
Ensembl chrNW_004936476:16,247,100...16,260,673
|
|
|
G |
Adam28 |
ADAM metallopeptidase domain 28 |
ameliorates |
ISO |
associated with lung adenocarcinoma; associated with lung carcinoma, breast carcinoma |
RGD |
PMID:22636800 PMID:26800504 |
RGD:11531771 RGD:153297785 |
NCBI chrNW_004936555:7,615,639...7,660,776
Ensembl chrNW_004936555:7,617,822...7,664,215
|
|
G |
Arhgap5 |
Rho GTPase activating protein 5 |
|
ISO |
associated with Mammary Neoplasms, Experimental |
RGD |
PMID:20860838 |
RGD:126848767 |
NCBI chrNW_004936494:6,562,092...6,624,015
Ensembl chrNW_004936494:6,562,069...6,623,175
|
|
G |
Arid2 |
AT-rich interaction domain 2 |
exacerbates |
ISO |
associated with hepatocellular carcinoma, |
RGD |
PMID:32071245 |
RGD:150340708 |
NCBI chrNW_004936512:4,020,303...4,199,390
Ensembl chrNW_004936512:4,020,966...4,196,459
|
|
G |
Azgp1 |
alpha-2-glycoprotein 1, zinc-binding |
ameliorates |
ISO |
associated with hepatocellular carcinoma; |
RGD |
PMID:26902423 PMID:27993894 |
RGD:153350132 RGD:153350133 |
NCBI chrNW_004936543:105,983...113,475
Ensembl chrNW_004936543:105,956...114,190
|
|
G |
Ca12 |
carbonic anhydrase 12 |
ameliorates |
ISO |
associated with breast cancer; |
RGD |
PMID:29786141 |
RGD:155226861 |
NCBI chrNW_004936471:23,876,889...23,929,720
Ensembl chrNW_004936471:23,876,812...23,929,987
|
|
G |
Cblb |
Cbl proto-oncogene B |
severity |
ISO |
associated with stomach carcinoma; |
RGD |
PMID:28334634 |
RGD:150540337 |
NCBI chrNW_004936701:1,157,790...1,353,375
Ensembl chrNW_004936701:1,157,797...1,353,388
|
|
G |
Ccng1 |
cyclin G1 |
|
ISO |
|
RGD |
PMID:30565428 |
RGD:151361205 |
NCBI chrNW_004936515:614,287...621,213
Ensembl chrNW_004936515:614,290...619,963
|
|
G |
Chd4 |
chromodomain helicase DNA binding protein 4 |
ameliorates |
ISO |
associated with human colon adenocarcinoma cells in a mouse model |
RGD |
PMID:28486105 |
RGD:153323299 |
NCBI chrNW_004936709:1,183,243...1,214,144
Ensembl chrNW_004936709:1,183,254...1,214,149
|
|
G |
Col10a1 |
collagen type X alpha 1 chain |
ameliorates |
ISO |
associated with H1299 cell |
RGD |
PMID:33324550 |
RGD:150429752 |
NCBI chrNW_004936824:734,499...741,674
Ensembl chrNW_004936824:734,488...769,010
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
ameliorates |
ISO |
associated with colorectal cancer; human cells in mouse model associated with osteosarcoma and melanoma associated with nasopharynx carcinoma; human cells in mouse model |
RGD |
PMID:16000558 PMID:18071913 PMID:26498029 PMID:31938138 |
RGD:151665329 RGD:151893515 RGD:152023752 RGD:152177473 |
NCBI chrNW_004936469:39,794,613...39,798,448
Ensembl chrNW_004936469:39,794,584...39,798,459
|
|
G |
Ddr1 |
discoidin domain receptor tyrosine kinase 1 |
|
ISO |
|
RGD |
PMID:29483153 |
RGD:151347599 |
NCBI chrNW_004936837:523,227...538,799
Ensembl chrNW_004936837:523,266...538,833
|
|
G |
Ddr2 |
discoidin domain receptor tyrosine kinase 2 |
exacerbates |
ISO |
associated with tongue squamous cell carcinoma; |
RGD |
PMID:24556606 |
RGD:150429746 |
NCBI chrNW_004936831:799,948...946,139
Ensembl chrNW_004936831:865,965...946,139
|
|
G |
Fasn |
fatty acid synthase |
|
ISO |
associated with head and neck squamous cell carcinoma |
RGD |
PMID:20604875 |
RGD:126790467 |
NCBI chrNW_004936594:5,591,785...5,609,886
Ensembl chrNW_004936594:5,592,609...5,608,972
|
|
G |
Fosl2 |
FOS like 2, AP-1 transcription factor subunit |
|
ISO |
human cells in mouse model |
RGD |
PMID:30326930 |
RGD:153344557 |
NCBI chrNW_004936493:4,308,683...4,327,102
Ensembl chrNW_004936493:4,304,395...4,327,179
|
|
G |
Hilpda |
hypoxia inducible lipid droplet associated |
|
ISO |
human cells in mouse model |
RGD |
PMID:31142329 |
RGD:153344574 |
NCBI chrNW_004936479:15,582,260...15,583,213
Ensembl chrNW_004936479:15,582,260...15,607,428
|
|
G |
Iqsec1 |
IQ motif and Sec7 domain ArfGEF 1 |
|
ISO |
human cells in mouse model |
RGD |
PMID:18084281 |
RGD:153344604 |
NCBI chrNW_004936898:318,564...425,785
Ensembl chrNW_004936898:337,400...425,859
|
|
G |
Itgav |
integrin subunit alpha V |
treatment |
ISO |
human cells in rat model |
RGD |
PMID:20841470 |
RGD:152998949 |
NCBI chrNW_004936506:10,750,116...10,839,018
Ensembl chrNW_004936506:10,750,101...10,839,303
|
|
G |
Map3k1 |
mitogen-activated protein kinase kinase kinase 1 |
ameliorates |
ISO |
associated with breast carcinoma |
RGD |
PMID:16568086 |
RGD:150573808 |
NCBI chrNW_004936480:11,082,811...11,156,691
Ensembl chrNW_004936480:11,083,605...11,156,691
|
|
G |
Map3k8 |
mitogen-activated protein kinase kinase kinase 8 |
ameliorates |
ISO |
associated with clear cell renal cell carcinoma |
RGD |
PMID:23982215 |
RGD:151356974 |
NCBI chrNW_004936613:3,791,684...3,813,857
Ensembl chrNW_004936613:3,791,681...3,813,892
|
|
G |
Nf2 |
NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor |
|
ISO |
associated with hepatocellular carcinoma |
RGD |
PMID:26443326 |
RGD:11076529 |
NCBI chrNW_004936657:3,536,212...3,622,999
Ensembl chrNW_004936657:3,536,141...3,623,821
|
|
G |
Ntrk3 |
neurotrophic receptor tyrosine kinase 3 |
ameliorates |
ISO |
associated with mammary carcinoma |
RGD |
PMID:20802235 |
RGD:150520014 |
NCBI chrNW_004936483:13,912,904...14,291,881
Ensembl chrNW_004936483:13,909,109...14,291,887
|
|
G |
Pagr1 |
PAXIP1 associated glutamate rich protein 1 |
|
ISO |
human cells in mouse model |
RGD |
PMID:33833989 |
RGD:153344568 |
NCBI chrNW_004936501:12,657,092...12,660,106
Ensembl chrNW_004936501:12,656,435...12,660,067
|
|
G |
Ptprb |
protein tyrosine phosphatase receptor type B |
treatment |
ISO |
|
RGD |
PMID:23899555 |
RGD:151660352 |
NCBI chrNW_004936545:8,150,766...8,235,674
Ensembl chrNW_004936545:8,147,291...8,235,715
|
|
G |
Rictor |
RPTOR independent companion of MTOR complex 2 |
|
ISO |
human cells in mouse model |
RGD |
PMID:20978191 PMID:29809146 |
RGD:152995469 RGD:152995516 |
NCBI chrNW_004936518:3,198,312...3,314,393
Ensembl chrNW_004936518:3,198,337...3,310,000
|
|
G |
Rptor |
regulatory associated protein of MTOR complex 1 |
|
ISO |
|
RGD |
PMID:29809146 |
RGD:152995516 |
NCBI chrNW_004936594:4,427,225...4,758,081
Ensembl chrNW_004936594:4,427,169...4,760,120
|
|
G |
Sf3b4 |
splicing factor 3b subunit 4 |
|
ISO |
human cells in mouse model |
RGD |
PMID:30391496 |
RGD:155804298 |
NCBI chrNW_004936580:260,013...265,057
|
|
G |
Sox30 |
SRY-box transcription factor 30 |
ameliorates |
ISO |
|
RGD |
PMID:29739711 |
RGD:151660333 |
NCBI chrNW_004936515:5,501,315...5,537,946
Ensembl chrNW_004936515:5,458,393...5,537,946
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
treatment ameliorates |
ISO |
associated with breast cancer; associated with nasopharynx carcinoma; |
RGD |
PMID:15753384 PMID:27078847 |
RGD:150521726 RGD:1581400 |
NCBI chrNW_004936561:3,826,802...3,844,406
Ensembl chrNW_004936561:3,825,787...3,844,483
|
|
|
G |
Adam28 |
ADAM metallopeptidase domain 28 |
|
ISO |
associated with breast cancer;DNA:hypermethylation: |
RGD |
PMID:25620615 |
RGD:153298970 |
NCBI chrNW_004936555:7,615,639...7,660,776
Ensembl chrNW_004936555:7,617,822...7,664,215
|
|
G |
Aicda |
activation induced cytidine deaminase |
|
ISO |
associated with stomach cancer;protein:increased expression:stomach (human) |
RGD |
PMID:21538122 |
RGD:127285638 |
NCBI chrNW_004936870:25,039...34,601
Ensembl chrNW_004936870:25,039...34,601
|
|
G |
Angptl4 |
angiopoietin like 4 |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:17130448 |
|
NCBI chrNW_004936588:5,188,866...5,194,924
Ensembl chrNW_004936588:5,188,850...5,194,931
|
|
G |
Anxa1 |
annexin A1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19381893 |
|
NCBI chrNW_004936503:9,124,314...9,142,372
Ensembl chrNW_004936503:9,124,264...9,142,413
|
|
G |
Aqp3 |
aquaporin 3 (Gill blood group) |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21401805 |
|
NCBI chrNW_004936524:1,963,427...1,969,977
Ensembl chrNW_004936524:1,963,247...1,969,998
|
|
G |
Arhgap5 |
Rho GTPase activating protein 5 |
|
ISO |
associated with nasopharynx carcinoma;mRNA, protein:increased expression: epithelium of nasopharynx |
RGD |
PMID:25961434 |
RGD:11056278 |
NCBI chrNW_004936494:6,562,092...6,624,015
Ensembl chrNW_004936494:6,562,069...6,623,175
|
|
G |
Asxl1 |
ASXL transcriptional regulator 1 |
|
ISO |
associated with colorectal cancer |
RGD |
PMID:32317519 |
RGD:126779580 |
NCBI chrNW_004936485:19,218,494...19,297,188
Ensembl chrNW_004936485:19,227,400...19,298,912
|
|
G |
Axl |
AXL receptor tyrosine kinase |
|
ISO |
associated Pancreatic Neoplasms |
RGD |
PMID:19252414 |
RGD:2325833 |
NCBI chrNW_004936661:3,658,140...3,687,290
Ensembl chrNW_004936661:3,657,831...3,687,816
|
|
G |
Bag1 |
BAG cochaperone 1 |
disease_progression |
ISO |
associated with Breast Neoplasms:protein:increased expression:breast |
RGD |
PMID:18430249 |
RGD:2292908 |
NCBI chrNW_004936524:1,793,001...1,804,145
Ensembl chrNW_004936524:1,791,119...1,804,151
|
|
G |
Bambi |
BMP and activin membrane bound inhibitor |
|
ISO |
associated with stomach cancer; protein:increased expression: : |
RGD |
PMID:24752577 |
RGD:14390158 |
NCBI chrNW_004936613:3,098,549...3,103,868
Ensembl chrNW_004936613:3,098,159...3,103,868
|
|
G |
Barhl2 |
BarH like homeobox 2 |
|
ISO |
associated with oral squamous cell carcinoma; mRNA:decreased expression:mouth mucosa |
RGD |
PMID:27542258 |
RGD:14390167 |
NCBI chrNW_004936537:8,129,213...8,134,744
Ensembl chrNW_004936537:8,129,207...8,135,237
|
|
G |
Bcl2 |
BCL2 apoptosis regulator |
|
ISO |
associated with Breast Neoplasms;protein:increased expression:lymph node |
RGD |
PMID:18217456 |
RGD:2293013 |
NCBI chrNW_004936497:2,209,136...2,373,580
Ensembl chrNW_004936497:2,210,334...2,210,921
|
|
G |
Bik |
BCL2 interacting killer |
|
ISO |
associated with cholangiocarcinoma;DNA:CNV:: |
RGD |
PMID:16865775 |
RGD:14394820 |
|
|
G |
Birc5 |
baculoviral IAP repeat containing 5 |
disease_progression |
ISO |
associated with Breast Neoplasms associated with Cervix Neoplasms;mRNA:splice variant |
RGD |
PMID:17285241 PMID:17877643 |
RGD:2293098 RGD:2293103 |
NCBI chrNW_004936594:2,812,165...2,820,618
Ensembl chrNW_004936594:2,812,238...2,820,636
|
|
G |
Braf |
B-Raf proto-oncogene, serine/threonine kinase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:29426936 |
|
NCBI chrNW_004936592:4,728,371...4,833,830
Ensembl chrNW_004936592:4,737,011...4,834,664
|
|
G |
Brd7 |
bromodomain containing 7 |
severity |
ISO |
protein:increased expression:lung: |
RGD |
PMID:22008115 |
RGD:9586442 |
NCBI chrNW_004936475:3,394,423...3,432,998
Ensembl chrNW_004936475:3,393,373...3,433,103
|
|
G |
Bsg |
basigin (Ok blood group) |
disease_progression |
ISO |
associated with Breast Neoplasms |
RGD |
PMID:16004819 |
RGD:2289055 |
NCBI chrNW_004936588:181,688...189,795
Ensembl chrNW_004936588:181,576...189,287
|
|
G |
Btk |
Bruton tyrosine kinase |
disease_progression |
ISO |
associated with lung adenocarcinoma;protein:increased expression:lung (human) |
RGD |
PMID:31200752 |
RGD:151347847 |
NCBI chrNW_004936813:429,400...467,481
Ensembl chrNW_004936813:429,224...463,441
|
|
G |
Ca9 |
carbonic anhydrase 9 |
|
ISO |
associated with Cervix Neoplasms |
RGD |
PMID:17233814 |
RGD:2293196 |
NCBI chrNW_004936524:3,672,393...3,678,630
Ensembl chrNW_004936524:3,672,541...3,678,433
|
|
G |
Cab39 |
calcium binding protein 39 |
|
ISO |
associated with pancreatic cancer;RNA:increased expression:pancreas |
RGD |
PMID:28197410 |
RGD:14398834 |
NCBI chrNW_004936525:5,955,252...6,002,917
Ensembl chrNW_004936525:5,954,978...6,032,644
|
|
G |
Casp9 |
caspase 9 |
|
ISO |
associated with Carcinoma, Non-Small-Cell Lung;DNA:SNP:exon:rs1052576 (human) |
RGD |
PMID:17285546 |
RGD:13434907 |
NCBI chrNW_004936474:3,178,097...3,196,130
|
|
G |
Cav1 |
caveolin 1 |
disease_progression |
ISO |
associated with Melanoma |
RGD |
PMID:22134245 |
RGD:8661767 |
NCBI chrNW_004936589:2,504,235...2,536,778
Ensembl chrNW_004936589:2,504,224...2,537,170
|
|
G |
Cbl |
Cbl proto-oncogene |
|
ISO |
associated with stomach carcinoma;protein:increased expression:stomach |
RGD |
PMID:31611438 |
RGD:126925223 |
NCBI chrNW_004936542:4,136,389...4,235,746
Ensembl chrNW_004936542:4,136,511...4,228,288
|
|
G |
Cblb |
Cbl proto-oncogene B |
|
ISO |
associated with stomach carcinoma; |
RGD |
PMID:20038312 |
RGD:150540338 |
NCBI chrNW_004936701:1,157,790...1,353,375
Ensembl chrNW_004936701:1,157,797...1,353,388
|
|
G |
Ccnd2 |
cyclin D2 |
|
ISO |
associated with colorectal cancer;protein:increased expression:colorectum |
RGD |
PMID:19508551 |
RGD:151665111 |
NCBI chrNW_004936606:4,474,801...4,496,158
Ensembl chrNW_004936606:4,474,749...4,496,810
|
|
G |
Ccne1 |
cyclin E1 |
|
ISO |
associated with Carcinoma, Transitional Cell;protein:decreased expression |
RGD |
PMID:16949911 |
RGD:2289266 |
NCBI chrNW_004936570:5,536,817...5,547,880
Ensembl chrNW_004936570:5,536,672...5,548,008
|
|
G |
Ccnh |
cyclin H |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:30705370 |
|
NCBI chrNW_004936469:5,933,163...5,952,190
Ensembl chrNW_004936469:5,935,131...5,952,460
|
|
G |
Cd274 |
CD274 molecule |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:16530813 |
|
NCBI chrNW_004936539:132,870...145,288
Ensembl chrNW_004936539:132,868...143,602
|
|
G |
Cd40 |
CD40 molecule |
|
ISO |
associated with breast cancer;DNA:snps:5' utr, intron:c.-1T>C, c.51+914T>G (rs1883832, rs4810485) (human) |
RGD |
PMID:21912605 |
RGD:8547780 |
NCBI chrNW_004936514:6,936,915...6,947,246
Ensembl chrNW_004936514:6,936,572...6,947,280
|
|
G |
Cd44 |
CD44 molecule (IN blood group) |
|
ISO |
associated with Breast Neoplasms, Colorectal Neoplasms, Stomach Neoplasms;mRNA, protein:splice variant, increased expression:breast, large intestine, stomach |
RGD |
PMID:16425351 |
RGD:2289356 |
NCBI chrNW_004936533:2,949,026...3,033,166
|
|
G |
Cdh1 |
cadherin 1 |
|
ISO |
associated with Breast Neoplasms associated with Cervix Neoplasms |
RGD |
PMID:17649807 PMID:18097581 |
RGD:2289498 RGD:2296046 |
NCBI chrNW_004936475:18,990,529...19,065,954
Ensembl chrNW_004936475:18,990,474...19,067,203
|
|
G |
Cdkn1a |
cyclin dependent kinase inhibitor 1A |
|
ISO |
associated with Eyelid Neoplasms; associated with Oral Squamous Cell Carcinoma; |
RGD |
PMID:15817070 PMID:19628749 |
RGD:8661799 RGD:8662374 |
NCBI chrNW_004936476:22,717,308...22,725,127
Ensembl chrNW_004936476:22,717,260...22,725,182
|
|
G |
Cdkn1b |
cyclin dependent kinase inhibitor 1B |
|
ISO |
associated with Breast Neoplasms associated with non-small cell lung carcinoma |
RGD |
PMID:12015771 PMID:28601655 |
RGD:13673921 RGD:2293607 |
NCBI chrNW_004936587:4,573,166...4,578,480
Ensembl chrNW_004936587:4,572,728...4,578,461
|
|
G |
Cldn1 |
claudin 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:33665778 |
|
NCBI chrNW_004936578:98,489...113,125
Ensembl chrNW_004936578:98,273...113,153
|
|
G |
Clptm1l |
CLPTM1 like |
|
ISO |
associated with esophagus squamous cell carcinoma; mRNA:increased expression:esophagus |
RGD |
PMID:25480402 |
RGD:150530497 |
NCBI chrNW_004936815:421,996...445,577
Ensembl chrNW_004936815:428,920...445,750
|
|
G |
Clu |
clusterin |
|
ISO |
associated with breast cancer;DNA:snp:promoter:g.27611345C>G (rs9331888) (human) |
RGD |
PMID:22037783 |
RGD:8963167 |
NCBI chrNW_004936675:499,745...513,515
Ensembl chrNW_004936675:499,199...513,836
|
|
G |
Comt |
catechol-O-methyltransferase |
|
ISO |
associated with breast cancer;DNA:missense mutation:cds:p.V108/158M (human) |
RGD |
PMID:10755383 |
RGD:8662330 |
NCBI chrNW_004936619:3,847,059...3,883,866
Ensembl chrNW_004936619:3,876,299...3,882,747
|
|
G |
Crp |
C-reactive protein |
susceptibility |
ISO |
associated with Breast Neoplasm; DNA:polymorphism: :1846C>T(rs1205)(human) |
RGD |
PMID:24633920 |
RGD:9580226 |
NCBI chrNW_004936740:885,855...888,854
Ensembl chrNW_004936740:883,272...890,606
|
|
G |
Csf1r |
colony stimulating factor 1 receptor |
|
ISO |
associated with Breast Neoplasms |
RGD |
PMID:14734466 |
RGD:2293711 |
NCBI chrNW_004936504:4,898,947...4,927,195
Ensembl chrNW_004936504:4,898,945...4,928,923
|
|
G |
Ctla4 |
cytotoxic T-lymphocyte associated protein 4 |
|
ISO |
associated with Prostatic Neoplasms |
RGD |
PMID:10611340 |
RGD:4891523 |
NCBI chrNW_004936631:484,356...489,643
Ensembl chrNW_004936631:484,356...489,643
|
|
G |
Ctnna1 |
catenin alpha 1 |
|
ISO |
associated with Breast Neoplasms |
RGD |
PMID:12047765 |
RGD:2289795 |
NCBI chrNW_004936531:7,865,907...8,036,020
Ensembl chrNW_004936531:7,865,820...8,037,935
|
|
G |
Ctnnb1 |
catenin beta 1 |
|
ISO |
associated with Breast Neoplasms;protein:decreased expression |
RGD |
PMID:17908479 |
RGD:2289813 |
NCBI chrNW_004936473:29,999,542...30,034,610
Ensembl chrNW_004936473:29,999,562...30,038,293
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
disease_progression |
ISO |
associated with stomach cancer;mRNA:increased expression:stomach (human) |
RGD |
PMID:21633638 |
RGD:152023624 |
NCBI chrNW_004936617:4,224,131...4,239,080
Ensembl chrNW_004936617:4,224,131...4,238,796
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
|
ISO |
associated with nasopharynx carcinoma; protein:increased expression:lymph node (human) |
RGD |
PMID:16000558 |
RGD:151893515 |
NCBI chrNW_004936469:39,794,613...39,798,448
Ensembl chrNW_004936469:39,794,584...39,798,459
|
|
G |
Ddr1 |
discoidin domain receptor tyrosine kinase 1 |
severity |
ISO |
mRNA, protein:increased expression:mouth (human) mRNA:increased expression:kidney, lymph nodes (human) |
RGD |
PMID:27020590 PMID:31253192 |
RGD:151347620 RGD:151347863 |
NCBI chrNW_004936837:523,227...538,799
Ensembl chrNW_004936837:523,266...538,833
|
|
G |
Ddr2 |
discoidin domain receptor tyrosine kinase 2 |
disease_progression |
ISO |
associated with oral squamous cell carcinoma |
RGD |
PMID:29945346 |
RGD:150429700 |
NCBI chrNW_004936831:799,948...946,139
Ensembl chrNW_004936831:865,965...946,139
|
|
G |
Dnmt3b |
DNA methyltransferase 3 beta |
|
ISO |
associated with Carcinoma, Pancreatic Ductal; |
RGD |
PMID:22919364 |
RGD:9589121 |
NCBI chrNW_004936485:19,547,836...19,570,716
|
|
G |
Ebag9 |
estrogen receptor binding site associated antigen 9 |
|
ISO |
associated with Breast Neoplasms;protein:increased expression:breast associated with Prostatic Neoplasm;protein:increased expression:prostate gland, lymph node |
RGD |
PMID:12054692 PMID:12845666 PMID:17187007 |
RGD:2289847 RGD:2289856 RGD:2298489 |
NCBI chrNW_004936470:35,449,920...35,473,635
Ensembl chrNW_004936470:35,450,292...35,473,110
|
|
G |
Egfr |
epidermal growth factor receptor |
treatment |
ISO |
associated with Squamous Cell Carcinoma of the Tongue |
RGD |
PMID:19380367 |
RGD:8551769 |
NCBI chrNW_004936678:365,005...560,546
Ensembl chrNW_004936678:365,834...436,528
|
|
G |
Ehmt2 |
euchromatic histone lysine methyltransferase 2 |
|
ISO |
associated with Melanoma; associated with Esophageal Squamous Cell Carcinoma; |
RGD |
PMID:24658378 PMID:24805087 |
RGD:9590069 RGD:9590071 |
NCBI chrNW_004936727:1,648,451...1,663,294
Ensembl chrNW_004936727:1,648,448...1,663,455
|
|
G |
Epha2 |
EPH receptor A2 |
|
ISO |
protein:increased expression:esophagus (human) |
RGD |
PMID:33833989 |
RGD:153344568 |
NCBI chrNW_004936474:3,648,395...3,673,856
Ensembl chrNW_004936474:3,648,550...3,673,861
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
disease_progression |
ISO |
associated with Carcinoma, Transitional Cell;protein:increased expression:urinary bladder associated with lung adenocarcinoma; protein:increased expression:lung (human) CTD Direct Evidence: marker/mechanism associated with Breast Neoplasms;DNA, protein:polymorphism, increased expression:serum:p.I655V |
RGD CTD |
PMID:18097576 PMID:18237248 PMID:21532492 PMID:21966491 |
RGD:153344600 RGD:2289925 RGD:2289926 |
NCBI chrNW_004936490:14,887,062...14,910,038
Ensembl chrNW_004936490:14,887,043...14,909,956
|
|
G |
Erbb3 |
erb-b2 receptor tyrosine kinase 3 |
|
ISO |
associated with Prostatic Neoplasms;protein:increased expression, altered localization:lymph node, nucleus associated with head and neck squamous cell carcinoma |
RGD |
PMID:17634423 PMID:20604875 |
RGD:126790467 RGD:2289944 |
NCBI chrNW_004936646:497,783...515,247
Ensembl chrNW_004936646:498,749...513,297
|
|
G |
Erbb4 |
erb-b2 receptor tyrosine kinase 4 |
severity disease_progression |
ISO |
associated with oral squamous cell carcinoma associated with colorectal adenocarcinoma associated with lung non-small cell carcinoma |
RGD |
PMID:16507107 PMID:21324275 PMID:27444519 |
RGD:126781762 RGD:126781766 RGD:126790471 |
NCBI chrNW_004936586:4,065,767...5,100,690
Ensembl chrNW_004936586:4,066,498...5,100,035
|
|
G |
Fas |
Fas cell surface death receptor |
susceptibility |
ISO |
associated with Cervix Neoplasms;DNA:polymorphism:promoter:-1377G>A |
RGD |
PMID:18068525 |
RGD:2298509 |
NCBI chrNW_004936735:209,369...234,582
|
|
G |
Fgf1 |
fibroblast growth factor 1 |
|
ISO |
associated with Cervix Neoplasms;mRNA:increased expression:lymph node |
RGD |
PMID:17242701 |
RGD:2290286 |
NCBI chrNW_004936504:11,590,687...11,684,410
Ensembl chrNW_004936504:11,590,637...11,685,194
|
|
G |
Fgfr2 |
fibroblast growth factor receptor 2 |
|
ISO |
associated with breast cancer;DNA:snp:intron:c.109+7033T>A (rs1219648) (human) |
RGD |
PMID:20640597 |
RGD:7394846 |
NCBI chrNW_004936486:10,506,680...10,606,272
Ensembl chrNW_004936486:10,507,097...10,602,019
|
|
G |
Flt3 |
fms related receptor tyrosine kinase 3 |
disease_progression |
ISO |
associated with Prostatic Neoplasms |
RGD |
PMID:14566827 |
RGD:2302210 |
NCBI chrNW_004936472:23,169,967...23,239,178
Ensembl chrNW_004936472:23,170,470...23,256,904
|
|
G |
Foxa1 |
forkhead box A1 |
|
ISO |
associated with lung non-small cell carcinoma; mRNA:increased expression: : |
RGD |
PMID:29115441 |
RGD:151665751 |
NCBI chrNW_004936494:11,529,546...11,535,224
Ensembl chrNW_004936494:11,529,546...11,535,224
|
|
G |
Foxp1 |
forkhead box P1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:25485836 |
|
NCBI chrNW_004936603:2,631,781...3,146,104
Ensembl chrNW_004936603:2,632,274...2,830,324
|
|
G |
Gpx3 |
glutathione peroxidase 3 |
|
ISO |
associated with stomach carcinoma; DNA:hypermethylation:promoter |
RGD |
PMID:23071548 |
RGD:151665353 |
NCBI chrNW_004936647:3,904,787...3,914,223
Ensembl chrNW_004936647:3,906,113...3,913,498
|
|
G |
Grik2 |
glutamate ionotropic receptor kainate type subunit 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:30705370 |
|
NCBI chrNW_004936651:2,756,559...3,401,806
Ensembl chrNW_004936651:2,762,380...3,401,808
|
|
G |
Hmgb1 |
high mobility group box 1 |
|
ISO |
associated with Adenocarcinoma, Colon |
RGD |
PMID:20616616 |
RGD:10402080 |
NCBI chrNW_004936472:25,236,728...25,246,585
Ensembl chrNW_004936472:25,236,728...25,246,580
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
|
ISO |
associated with Breast Neoplasms |
RGD |
PMID:21590495 |
RGD:8547712 |
NCBI chrNW_004936659:616,570...627,172
Ensembl chrNW_004936659:616,752...627,174
|
|
G |
Ier2 |
immediate early response 2 |
|
ISO |
|
RGD |
PMID:22120713 |
RGD:153323322 |
NCBI chrNW_004936659:2,176,962...2,179,900
Ensembl chrNW_004936659:2,178,312...2,178,983
|
|
G |
Il13 |
interleukin 13 |
|
ISO |
associated with Melanoma, Cutaneous Malignant;mRNA:increased expression:lymph node |
RGD |
PMID:17545514 |
RGD:8549587 |
NCBI chrNW_004936647:2,529,933...2,532,503
Ensembl chrNW_004936647:2,530,491...2,532,373
|
|
G |
Il18 |
interleukin 18 |
|
ISO |
associated with Breast Neoplasms;protein:increased expression:serum |
RGD |
PMID:12902898 |
RGD:8655867 |
NCBI chrNW_004936612:2,306,963...2,325,086
Ensembl chrNW_004936612:2,306,875...2,325,189
|
|
G |
Ing4 |
inhibitor of growth family member 4 |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:27806345 |
|
NCBI chrNW_004936709:1,140,485...1,147,982
Ensembl chrNW_004936709:1,140,345...1,149,843
|
|
G |
Iqsec1 |
IQ motif and Sec7 domain ArfGEF 1 |
disease_progression |
ISO |
associated with lung adenocarcinoma; protein:increased expression:lung (human) |
RGD |
PMID:21966491 |
RGD:153344600 |
NCBI chrNW_004936898:318,564...425,785
Ensembl chrNW_004936898:337,400...425,859
|
|
G |
Itgb1 |
integrin subunit beta 1 |
|
ISO |
associated with non-small cell lung carcinoma, |
RGD |
PMID:28537888 |
RGD:13792830 |
NCBI chrNW_004936574:1,465,981...1,495,717
Ensembl chrNW_004936574:1,465,897...1,495,762
|
|
G |
Kcnj12 |
potassium inwardly rectifying channel subfamily J member 12 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:34755307 |
|
NCBI chrNW_004936741:266,311...303,947
|
|
G |
Kdr |
kinase insert domain receptor |
treatment |
ISO |
associated with Squamous Cell Carcinoma of the Tongue |
RGD |
PMID:19380367 |
RGD:8551769 |
NCBI chrNW_004936482:17,537,697...17,581,320
Ensembl chrNW_004936482:17,538,864...17,581,002
|
|
G |
Kiss1 |
KiSS-1 metastasis suppressor |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:21383688 |
|
NCBI chrNW_004936567:584,443...595,045
Ensembl chrNW_004936567:584,443...586,837
|
|
G |
Klf7 |
KLF transcription factor 7 |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:37734194 |
|
NCBI chrNW_004936631:3,327,555...3,412,206
Ensembl chrNW_004936631:3,329,681...3,412,252
|
|
G |
Kmt2d |
lysine methyltransferase 2D |
|
ISO |
associated with stomach cancer |
RGD |
PMID:30177394 |
RGD:150521710 |
NCBI chrNW_004936512:6,819,240...6,860,852
Ensembl chrNW_004936512:6,822,057...6,854,451
|
|
G |
Lamc2 |
laminin subunit gamma 2 |
|
ISO |
associated with lung squamous cell carcinoma; |
RGD |
PMID:23124251 |
RGD:13793371 |
NCBI chrNW_004936481:6,588,797...6,647,167
Ensembl chrNW_004936481:6,588,865...6,647,188
|
|
G |
LOC101964702 |
adhesion G protein-coupled receptor B1 |
disease_progression |
ISO |
associated with stomach cancer; |
RGD |
PMID:11172604 |
RGD:13831357 |
NCBI chrNW_004936470:9,247,749...9,313,230
Ensembl chrNW_004936470:9,248,319...9,313,230
|
|
G |
Lrrc59 |
leucine rich repeat containing 59 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:30705370 |
|
NCBI chrNW_004936490:11,296,590...11,308,379
Ensembl chrNW_004936490:11,296,530...11,310,946
|
|
G |
Macir |
macrophage immunometabolism regulator |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:30705370 |
|
NCBI chrNW_004936523:1,273,812...1,292,837
Ensembl chrNW_004936523:1,275,214...1,292,854
|
|
G |
Met |
MET proto-oncogene, receptor tyrosine kinase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:29426936 |
|
NCBI chrNW_004936589:2,280,803...2,390,179
Ensembl chrNW_004936589:2,280,799...2,390,179
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
disease_progression |
ISO |
associated with Carcinoma, Ductal, Breast associated with Tongue Neoplasms |
RGD |
PMID:23107277 PMID:23280016 |
RGD:8547824 RGD:8655998 |
NCBI chrNW_004936475:7,801,356...7,825,831
Ensembl chrNW_004936475:7,801,277...7,825,851
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
disease_progression |
ISO |
associated with Tongue Neoplasms associated with Carcinoma, Non-Small-Cell Lung;protein:increased expression:serum associated with Endometrial Neoplasms;protein:increased expression:endometrium |
RGD |
PMID:12487935 PMID:20704821 PMID:23107277 |
RGD:2298523 RGD:5129215 RGD:8547824 |
NCBI chrNW_004936514:7,038,240...7,045,873
Ensembl chrNW_004936514:7,037,639...7,045,793
|
|
G |
Msh2 |
mutS homolog 2 |
|
ISO |
associated with laryngeal squamous cell carcinoma |
RGD |
PMID:24459922 |
RGD:126848797 |
NCBI chrNW_004936508:4,943,987...5,013,356
Ensembl chrNW_004936508:4,944,007...5,013,356
|
|
G |
Mta1 |
metastasis associated 1 |
|
ISO |
associated with Carcinoma, Non-Small-Cell Lung;mRNA:increased expression:lung |
RGD |
PMID:11804687 |
RGD:9588220 |
NCBI chrNW_004936621:117,785...140,917
Ensembl chrNW_004936621:117,785...140,926
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:30705370 |
|
NCBI chrNW_004936474:158,376...282,310
Ensembl chrNW_004936474:157,590...282,342
|
|
G |
Muc1 |
mucin 1, cell surface associated |
|
ISO |
associated with Gallbladder Neoplasms;protein:altered localization:gallbladder associated with Esophageal Neoplasms associated with Common Bile Duct Neoplasms associated with Carcinoma, Renal Cell; |
RGD |
PMID:10390012 PMID:11295067 PMID:16222735 PMID:21339746 |
RGD:2324649 RGD:2324860 RGD:7245968 RGD:7349383 |
NCBI chrNW_004936580:4,691,870...4,694,092
|
|
G |
Muc5ac |
mucin 5AC, oligomeric mucus/gel-forming |
|
ISO |
associated with chloangiocarcinoma;protein:increased expression:bile duct |
RGD |
PMID:16842244 |
RGD:2325168 |
NCBI chrNW_004936816:129,926...159,396
|
|
G |
Ncam1 |
neural cell adhesion molecule 1 |
|
ISO |
|
RGD |
PMID:10086383 |
RGD:2326067 |
NCBI chrNW_004936612:1,262,557...1,556,281
Ensembl chrNW_004936612:1,262,544...1,556,016
|
|
G |
Nme2 |
NME/NM23 nucleoside diphosphate kinase 2 |
|
ISO |
associated with Cervix Neoplasms; associated with Endometrial Neoplasms |
RGD |
PMID:8855975 |
RGD:2299062 |
NCBI chrNW_004936490:10,634,788...10,640,182
Ensembl chrNW_004936490:10,633,454...10,649,914
|
|
G |
Nos3 |
nitric oxide synthase 3 |
susceptibility |
ISO |
associated with Breast Neoplasms;DNA:polymorphisms:promoter, exon:-786T>C,p.E298D (human) |
RGD |
PMID:17262178 |
RGD:2292070 |
NCBI chrNW_004936527:6,427,147...6,445,770
Ensembl chrNW_004936527:6,427,093...6,446,534
|
|
G |
Ogg1 |
8-oxoguanine DNA glycosylase |
|
ISO |
associated with breast cancer;DNA:missense mutation:cds:p.S326C (rs1052133) (human) |
RGD |
PMID:18977234 |
RGD:8657156 |
NCBI chrNW_004936602:3,411,106...3,418,826
Ensembl chrNW_004936602:3,413,282...3,418,831
|
|
G |
Pagr1 |
PAXIP1 associated glutamate rich protein 1 |
disease_progression |
ISO |
protein:decreased expression:esophagus (human) |
RGD |
PMID:33833989 |
RGD:153344568 |
NCBI chrNW_004936501:12,657,092...12,660,106
Ensembl chrNW_004936501:12,656,435...12,660,067
|
|
G |
Pdgfa |
platelet derived growth factor subunit A |
|
ISO |
associated with Breast Neoplasms;mRNA:increased expression:breast |
RGD |
PMID:8619189 |
RGD:2292155 |
NCBI chrNW_004936754:808,894...828,554
Ensembl chrNW_004936754:808,213...828,613
|
|
G |
Pdgfb |
platelet derived growth factor subunit B |
|
ISO |
associated with Breast Neoplasms;mRNA:increased expression:lymph node |
RGD |
PMID:17674348 |
RGD:2292173 |
NCBI chrNW_004936492:2,353,840...2,368,573
Ensembl chrNW_004936492:2,353,841...2,368,573
|
|
G |
Pdpk1 |
3-phosphoinositide dependent protein kinase 1 |
|
ISO |
associated with non-small cell lung carcinoma;mRNA:increased expression:blood serum |
RGD |
PMID:25064732 |
RGD:13503320 |
NCBI chrNW_004936694:1,444,819...1,487,628
Ensembl chrNW_004936694:1,444,880...1,488,265 Ensembl chrNW_004936694:1,444,880...1,488,265
|
|
G |
Pdpn |
podoplanin |
|
ISO |
associated with Breast Neoplasms associated with Cervix Neoplasms |
RGD |
PMID:16528371 PMID:18165897 |
RGD:2292231 RGD:2292237 |
NCBI chrNW_004936474:1,751,159...1,779,011
Ensembl chrNW_004936474:1,750,944...1,781,156
|
|
G |
Pebp1 |
phosphatidylethanolamine binding protein 1 |
|
ISO |
associated with Breast Neoplasms associated with Cervix Neoplasms |
RGD |
PMID:16243812 PMID:18191186 |
RGD:2302867 RGD:2302868 |
NCBI chrNW_004936668:2,316,661...2,323,015
|
|
G |
Pik3ca |
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha |
|
ISO |
associated with Colorectal Neoplasms |
RGD |
PMID:25550888 |
RGD:13432030 |
NCBI chrNW_004936566:3,924,013...3,951,052
Ensembl chrNW_004936566:3,923,934...3,951,073
|
|
G |
Pik3cb |
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta |
|
ISO |
associated with Colorectal Neoplasms |
RGD |
PMID:25550888 |
RGD:13432030 |
NCBI chrNW_004936540:907,118...1,041,814
Ensembl chrNW_004936540:907,112...1,041,848
|
|
G |
Pip5k1a |
phosphatidylinositol-4-phosphate 5-kinase type 1 alpha |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:34755307 |
|
NCBI chrNW_004936580:1,399,492...1,448,398
Ensembl chrNW_004936580:1,399,954...1,446,769
|
|
G |
Pou5f1 |
POU class 5 homeobox 1 |
|
ISO |
associated with Seminoma; associated with Carcinoma, Embryonal |
RGD |
PMID:15386301 |
RGD:2292442 |
NCBI chrNW_004936837:827,568...838,933
|
|
G |
Pparg |
peroxisome proliferator activated receptor gamma |
|
ISO |
associated with Cholangiocarcinoma;protein:increased expression:bile duct epithelium |
RGD |
PMID:20021832 |
RGD:2317459 |
NCBI chrNW_004936602:1,230,907...1,368,588
Ensembl chrNW_004936602:1,230,907...1,304,743
|
|
G |
Prex1 |
phosphatidylinositol-3,4,5-trisphosphate dependent Rac exchange factor 1 |
|
ISO |
associated with Prostatic Neoplasms |
RGD |
PMID:19305425 |
RGD:2314605 |
NCBI chrNW_004936514:5,291,473...5,443,999
Ensembl chrNW_004936514:5,368,629...5,444,003
|
|
G |
Pten |
phosphatase and tensin homolog |
|
ISO |
associated with Prostatic Neoplasms;protein:decreased expression:prostate associated with Breast Neoplasms |
RGD |
PMID:17163422 PMID:17919877 |
RGD:2292499 RGD:2292507 |
NCBI chrNW_004936735:1,252,414...1,338,318
Ensembl chrNW_004936735:1,252,414...1,338,323
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
ISO |
associated with Biliary Tract Neoplasms associated with carcinoma, non-small-cell lung; DNA:SNP: :929G>C(human) associated with Breast Neoplasms |
RGD |
PMID:18159174 PMID:18353210 PMID:20016751 |
RGD:2300128 RGD:2317165 RGD:5135471 |
NCBI chrNW_004936481:3,821,564...3,828,086
|
|
G |
Ptk2 |
protein tyrosine kinase 2 |
|
ISO |
associated with lung squamous cell carcinoma; protein:increased tyrosine phosphorylation:lymph node |
RGD |
PMID:23906871 |
RGD:152176664 |
NCBI chrNW_004936470:10,379,855...10,578,531
Ensembl chrNW_004936470:10,379,872...10,578,543
|
|
G |
Ptpn13 |
protein tyrosine phosphatase non-receptor type 13 |
|
ISO |
associated with lung squamous cell carcinoma; protein:decreased expression:lymph node |
RGD |
PMID:23906871 |
RGD:152176664 |
NCBI chrNW_004936920:313,762...510,334
Ensembl chrNW_004936920:313,814...510,001
|
|
G |
Ramp2 |
receptor activity modifying protein 2 |
disease_progression |
ISO |
associated with colorectal cancer; protein:increased expression:lymph node (human) |
RGD |
PMID:23634287 |
RGD:151708733 |
NCBI chrNW_004936490:17,479,899...17,481,788
Ensembl chrNW_004936490:17,479,650...17,482,716
|
|
G |
Ramp3 |
receptor activity modifying protein 3 |
|
ISO |
associated with colorectal cancer; protein:increased expression:lymph node (human) |
RGD |
PMID:23634287 |
RGD:151708733 |
NCBI chrNW_004936478:19,977,618...20,001,366
Ensembl chrNW_004936478:19,977,539...20,004,838
|
|
G |
Rassf2 |
Ras association domain family member 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:17013896 |
|
NCBI chrNW_004936485:13,997,688...14,042,712
Ensembl chrNW_004936485:13,997,652...14,042,578
|
|
G |
Rbm10 |
RNA binding motif protein 10 |
|
ISO |
associated with lung adenocarcinoma;DNA:missense mutation:exon:p.R241C (c.763C>T) (human) |
RGD |
PMID:30405763 |
RGD:151356993 |
NCBI chrNW_004936502:12,923,890...12,952,179
Ensembl chrNW_004936502:12,925,910...12,955,470
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
|
ISO |
associated with Prostatic Neoplasms;protein:altered localization:nucleus, prostate gland |
RGD |
PMID:17020979 |
RGD:2298757 |
NCBI chrNW_004936599:3,800,142...3,810,583
Ensembl chrNW_004936599:3,801,636...3,809,813
|
|
G |
Ret |
ret proto-oncogene |
|
ISO |
associated with Pancreatic Neoplasms |
RGD |
PMID:18652760 |
RGD:2324925 |
NCBI chrNW_004936617:2,927,185...2,980,594
Ensembl chrNW_004936617:2,927,155...2,980,602
|
|
G |
Rhoa |
ras homolog family member A |
|
ISO |
associated with Bladder Neoplasms;protein:increased expression:lymph node associated with colorectal cancer |
RGD |
PMID:12855641 PMID:17597401 |
RGD:13432052 RGD:2298872 |
NCBI chrNW_004936529:1,000,050...1,045,655
Ensembl chrNW_004936529:999,935...1,045,681
|
|
G |
Rictor |
RPTOR independent companion of MTOR complex 2 |
|
ISO |
associated with breast ductal carcinoma; protein:increased expression:breast tumor, lymph node (human) |
RGD |
PMID:20978191 |
RGD:152995469 |
NCBI chrNW_004936518:3,198,312...3,314,393
Ensembl chrNW_004936518:3,198,337...3,310,000
|
|
G |
Sfn |
stratifin |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19381893 |
|
NCBI chrNW_004936474:11,274,927...11,279,427
Ensembl chrNW_004936474:11,246,534...11,279,433
|
|
G |
Skp2 |
S-phase kinase associated protein 2 |
|
ISO |
associated with Endometrial Neoplasms;protein:increased expression:endometrium |
RGD |
PMID:16080017 |
RGD:2315043 |
NCBI chrNW_004936518:5,635,856...5,664,057
Ensembl chrNW_004936518:5,637,331...5,664,778
|
|
G |
Slc7a5 |
solute carrier family 7 member 5 |
severity |
ISO |
associated with gastric adenocarcinoma;protein:increased expression: : associated with stomach carcinoma |
RGD |
PMID:21501294 PMID:25908107 |
RGD:11052781 RGD:151361203 |
NCBI chrNW_004936641:1,513,110...1,538,955
|
|
G |
Smad4 |
SMAD family member 4 |
|
ISO |
associated with Breast Neoplasms |
RGD |
PMID:11809701 |
RGD:2300007 |
NCBI chrNW_004936497:12,242,869...12,278,012
Ensembl chrNW_004936497:12,249,140...12,278,123
|
|
G |
Smo |
smoothened, frizzled class receptor |
|
ISO |
associated with colorectal cancer |
RGD |
PMID:30784110 |
RGD:150520177 |
NCBI chrNW_004936579:5,893,064...5,917,021
Ensembl chrNW_004936579:5,892,542...5,917,281
|
|
G |
Sncg |
synuclein gamma |
|
ISO |
|
RGD |
PMID:15221989 |
RGD:6478801 |
NCBI chrNW_004936804:16,869...21,684
Ensembl chrNW_004936804:16,614...21,969
|
|
G |
Socs2 |
suppressor of cytokine signaling 2 |
|
ISO |
associated with Prostatic Neoplasms |
RGD |
PMID:16707422 |
RGD:2298925 |
NCBI chrNW_004936507:10,013,982...10,015,480
Ensembl chrNW_004936507:10,012,101...10,014,456
|
|
G |
Socs3 |
suppressor of cytokine signaling 3 |
|
ISO |
associated with Breast Neoplasms |
RGD |
PMID:18097573 |
RGD:2298901 |
NCBI chrNW_004936594:2,932,297...2,935,358
Ensembl chrNW_004936594:2,933,747...2,934,451
|
|
G |
Sod2 |
superoxide dismutase 2 |
disease_progression |
ISO |
associated with tongue neoplasms; CTD Direct Evidence: marker/mechanism |
RGD CTD |
PMID:10853026 PMID:19381893 PMID:20618948 |
RGD:8547519 |
NCBI chrNW_004936489:11,178,338...11,191,601
Ensembl chrNW_004936489:11,178,015...11,191,781
|
|
G |
Sox2 |
SRY-box transcription factor 2 |
disease_progression |
ISO |
associated with Breast Neoplasms |
RGD |
PMID:24382260 |
RGD:8661670 |
NCBI chrNW_004936566:1,630,698...1,632,607
Ensembl chrNW_004936566:1,631,822...1,632,613
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
|
ISO |
associated with colon adenocarcinoma, |
RGD |
PMID:21282564 |
RGD:150520218 |
NCBI chrNW_004936561:3,826,802...3,844,406
Ensembl chrNW_004936561:3,825,787...3,844,483
|
|
G |
St14 |
ST14 transmembrane serine protease matriptase |
|
ISO |
associated with Endometrial Neoplasms |
RGD |
PMID:19443387 |
RGD:2315087 |
NCBI chrNW_004936572:2,137,820...2,182,674
Ensembl chrNW_004936572:2,137,332...2,182,742
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21549414 |
|
NCBI chrNW_004936490:17,119,189...17,178,402
Ensembl chrNW_004936490:17,117,290...17,178,402
|
|
G |
Stk11 |
serine/threonine kinase 11 |
|
ISO |
associated with Breast Neoplasms;protein:decreased expression |
RGD |
PMID:12114407 |
RGD:2291948 |
NCBI chrNW_004936588:579,816...601,033
Ensembl chrNW_004936588:579,816...603,654
|
|
G |
Tert |
telomerase reverse transcriptase |
disease_progression |
ISO |
associated with lung non-small cell carcinoma; |
RGD |
PMID:11679180 |
RGD:152977755 |
NCBI chrNW_004936815:468,987...492,666
Ensembl chrNW_004936815:469,020...491,697
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
|
ISO |
associated with Endometrial Neoplasms;protein:increased expression:endometrium |
RGD |
PMID:12487935 |
RGD:2298523 |
NCBI chrNW_004936502:13,345,936...13,350,170
Ensembl chrNW_004936502:13,345,832...13,350,248
|
|
G |
Timp3 |
TIMP metallopeptidase inhibitor 3 |
|
ISO |
associated with Breast Neoplasms;mRNA:increased expression:breast |
RGD |
PMID:12828172 |
RGD:2290437 |
NCBI chrNW_004936492:6,996,627...7,046,137
Ensembl chrNW_004936492:6,996,613...7,046,190
|
|
G |
Timp4 |
TIMP metallopeptidase inhibitor 4 |
|
ISO |
associated with Breast Neoplasms;mRNA:increased expression:breast |
RGD |
PMID:12828172 |
RGD:2290437 |
NCBI chrNW_004936602:1,488,993...1,496,108
Ensembl chrNW_004936602:1,489,545...1,495,478
|
|
G |
Tlr4 |
toll like receptor 4 |
|
ISO |
associated with Carcinoma, Ductal, Breast; |
RGD |
PMID:23338716 |
RGD:7794684 |
NCBI chrNW_004936487:6,519,140...6,532,018
Ensembl chrNW_004936487:6,518,441...6,533,095
|
|
G |
Tp53 |
tumor protein p53 |
|
ISO |
associated with Carcinoma, Squamous Cell; associated with Breast Neoplasms;DNA:missense mutation, duplication:cds, intron:p.R72P associated with Penile Neoplasms |
RGD |
PMID:18059331 PMID:18230179 PMID:18268397 |
RGD:2290533 RGD:2290534 RGD:8547790 |
NCBI chrNW_004936595:919,807...935,367
Ensembl chrNW_004936595:919,428...925,425
|
|
G |
Tp53bp1 |
tumor protein p53 binding protein 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:30705370 |
|
NCBI chrNW_004936471:6,589,395...6,668,242
Ensembl chrNW_004936471:6,589,564...6,668,305
|
|
G |
Trmt11 |
tRNA methyltransferase 11 homolog |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:30705370 |
|
NCBI chrNW_004936639:3,442,026...3,494,303
Ensembl chrNW_004936639:3,440,703...3,494,362
|
|
G |
Tsc2 |
TSC complex subunit 2 |
|
ISO |
associated with Breast Neoplasms |
RGD |
PMID:15951164 |
RGD:11568707 |
NCBI chrNW_004936694:1,958,152...1,993,373
Ensembl chrNW_004936694:1,958,154...1,993,363
|
|
G |
Tshr |
thyroid stimulating hormone receptor |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:9062474 |
|
NCBI chrNW_004936488:9,428,053...9,560,856
Ensembl chrNW_004936488:9,427,962...9,560,685
|
|
G |
Ttr |
transthyretin |
|
ISO |
associated with colorectal cancer;protein:decreased expresion:blood serum (human) |
RGD |
PMID:21074777 |
RGD:151665155 |
NCBI chrNW_004936682:1,628,489...1,635,495
Ensembl chrNW_004936682:1,628,341...1,635,566
|
|
G |
Tymp |
thymidine phosphorylase |
|
ISO |
associated with Breast Neoplasms associated with Cholangiocarcinoma |
RGD |
PMID:10685502 PMID:11927969 |
RGD:2293725 RGD:2325027 |
NCBI chrNW_004936629:315,609...320,356
Ensembl chrNW_004936629:315,610...319,076
|
|
G |
Vegfa |
vascular endothelial growth factor A |
|
ISO |
associated with Breast neoplasms; associated with Cervix Neoplasms |
RGD |
PMID:17597103 PMID:19783962 |
RGD:2315454 RGD:7421574 |
NCBI chrNW_004936476:16,245,134...16,261,180
Ensembl chrNW_004936476:16,247,100...16,260,673
|
|
G |
Vegfc |
vascular endothelial growth factor C |
exacerbates disease_progression |
ISO |
associated with Lymphatic Metastasis; associated with pancreatic adenocarcinoma;protein:increased expression:pancreas (human) associated with thyroid diseases;mRNA:increased expression:thyroid gland: associated with Prostatic Neoplasms associated with Breast Neoplasms associated with Carcinoma, Transitional Cell;protein:increased expression:urinary bladder associated with Cervix Neoplasms |
RGD |
PMID:12203051 PMID:15289890 PMID:17034609 PMID:18061373 PMID:19589137 PMID:19608016 PMID:19923084 More...
|
RGD:155630642 RGD:2315469 RGD:2315474 RGD:2315475 RGD:2315484 RGD:7483611 RGD:7488946 |
NCBI chrNW_004936516:7,217,543...7,332,531
Ensembl chrNW_004936516:7,217,543...7,332,559
|
|
G |
Vegfd |
vascular endothelial growth factor D |
|
ISO |
associated with Cervix Neoplasms associated with Breast Neoplasms |
RGD |
PMID:17951197 PMID:19589137 |
RGD:2315475 RGD:2315480 |
NCBI chrNW_004936470:4,761,827...4,794,751
Ensembl chrNW_004936470:4,762,332...4,793,938
|
|
G |
Wrap53 |
WD repeat containing antisense to TP53 |
|
ISO |
associated with lung non-small cell carcinoma; associated with esophagus squamous cell carcinoma; |
RGD |
PMID:24626331 PMID:31281482 |
RGD:21081513 RGD:21081532 |
NCBI chrNW_004936595:936,184...952,784
Ensembl chrNW_004936595:936,487...952,791
|
|
|
G |
Aco1 |
aconitase 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20390345 |
|
NCBI chrNW_004936524:1,081,672...1,134,971
Ensembl chrNW_004936524:1,081,696...1,134,971
|
|
G |
Actb |
actin beta |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:15654357 |
|
NCBI chrNW_004936765:667,107...670,627
Ensembl chrNW_004936765:667,053...670,672
|
|
G |
Adamts1 |
ADAM metallopeptidase with thrombospondin type 1 motif 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:23289900 |
|
NCBI chrNW_004936640:959,405...967,305
Ensembl chrNW_004936640:959,417...968,842
|
|
G |
Ahnak |
AHNAK nucleoprotein |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20388789 |
|
NCBI chrNW_004936581:702,579...792,762
|
|
G |
Ahr |
aryl hydrocarbon receptor |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:25826687 PMID:27752740 |
|
NCBI chrNW_004936546:3,737,908...3,783,492
Ensembl chrNW_004936546:3,737,851...3,783,588
|
|
G |
Alkbh8 |
alkB homolog 8, tRNA methyltransferase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27811057 |
|
NCBI chrNW_004936551:1,070,484...1,123,427
Ensembl chrNW_004936551:1,076,117...1,123,877
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20061081 |
|
NCBI chrNW_004936554:7,807,914...7,848,691
Ensembl chrNW_004936554:7,808,355...7,867,931
|
|
G |
Ambp |
alpha-1-microglobulin/bikunin precursor |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:14644129 |
|
NCBI chrNW_004936487:3,399,792...3,412,088
|
|
G |
Amotl1 |
angiomotin like 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:34480788 |
|
NCBI chrNW_004936674:163,889...285,523
Ensembl chrNW_004936674:156,552...223,685
|
|
G |
Angpt1 |
angiopoietin 1 |
|
ISO |
associated with Mammary Neoplasms, Animal;mRNA:increased expression:mammary gland |
RGD |
PMID:15459484 |
RGD:1626167 |
NCBI chrNW_004936470:37,105,469...37,328,183
Ensembl chrNW_004936470:37,105,466...37,328,190
|
|
G |
Angptl4 |
angiopoietin like 4 |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:17130448 |
|
NCBI chrNW_004936588:5,188,866...5,194,924
Ensembl chrNW_004936588:5,188,850...5,194,931
|
|
G |
Anxa1 |
annexin A1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:15654357 |
|
NCBI chrNW_004936503:9,124,314...9,142,372
Ensembl chrNW_004936503:9,124,264...9,142,413
|
|
G |
Anxa2 |
annexin A2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:15654357 |
|
NCBI chrNW_004936471:21,274,112...21,329,286
Ensembl chrNW_004936471:21,274,027...21,329,503
|
|
G |
Arf1 |
ARF GTPase 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27517156 |
|
NCBI chrNW_004936864:117,510...119,612
|
|
G |
Axl |
AXL receptor tyrosine kinase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26206560 |
|
NCBI chrNW_004936661:3,658,140...3,687,290
Ensembl chrNW_004936661:3,657,831...3,687,816
|
|
G |
Bcar1 |
BCAR1 scaffold protein, Cas family member |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21291860 |
|
NCBI chrNW_004936475:23,994,130...24,032,829
Ensembl chrNW_004936475:23,992,193...24,033,031
|
|
G |
Brms1 |
BRMS1 transcriptional repressor and anoikis regulator |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:27501413 |
|
NCBI chrNW_004936599:3,259,868...3,267,172
Ensembl chrNW_004936599:3,259,835...3,267,676
|
|
G |
Bsg |
basigin (Ok blood group) |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21165561 |
|
NCBI chrNW_004936588:181,688...189,795
Ensembl chrNW_004936588:181,576...189,287
|
|
G |
Calr |
calreticulin |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:15048980 |
|
NCBI chrNW_004936659:1,994,695...1,999,070
Ensembl chrNW_004936659:1,994,648...1,999,430
|
|
G |
Calu |
calumenin |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:15048980 |
|
NCBI chrNW_004936479:15,665,979...15,697,016
Ensembl chrNW_004936479:15,665,946...15,698,560
|
|
G |
Cat |
catalase |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:21749277 PMID:22580338 |
|
NCBI chrNW_004936533:3,601,270...3,637,128
Ensembl chrNW_004936533:3,600,955...3,637,422
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:18985009 |
|
NCBI chrNW_004936490:253,279...259,947
Ensembl chrNW_004936490:253,034...259,965
|
|
G |
Cd82 |
CD82 molecule |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:20075392 |
|
|
|
G |
Cdh1 |
cadherin 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism|therapeutic |
CTD |
PMID:19839049 PMID:22580338 |
|
NCBI chrNW_004936475:18,990,529...19,065,954
Ensembl chrNW_004936475:18,990,474...19,067,203
|
|
G |
Cdh2 |
cadherin 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27811057 |
|
NCBI chrNW_004936550:6,885,484...7,067,001
Ensembl chrNW_004936550:6,886,706...6,945,056
|
|
G |
Cfl1 |
cofilin 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:15048980 |
|
NCBI chrNW_004936599:3,678,724...3,682,314
Ensembl chrNW_004936599:3,677,804...3,682,307
|
|
G |
Chi3l1 |
chitinase 3 like 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21029458 |
|
NCBI chrNW_004936567:1,411,080...1,418,332
Ensembl chrNW_004936567:1,411,037...1,418,801
|
|
G |
Chrna7 |
cholinergic receptor nicotinic alpha 7 subunit |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:18844224 |
|
NCBI chrNW_004937351:32,324...46,871
Ensembl chrNW_004937351:34,921...47,246
|
|
G |
Cse1l |
chromosome segregation 1 like |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:34022224 |
|
NCBI chrNW_004936514:5,112,961...5,157,584
Ensembl chrNW_004936514:5,110,186...5,157,584
|
|
G |
Cstb |
cystatin B |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19747051 PMID:22287159 |
|
NCBI chrNW_004936500:502,444...503,307
Ensembl chrNW_004936500:502,237...503,578
|
|
G |
Ctbp2 |
C-terminal binding protein 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28414304 |
|
NCBI chrNW_004936486:13,173,280...13,261,257
Ensembl chrNW_004936486:13,173,301...13,261,259
|
|
G |
Ctnnb1 |
catenin beta 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:23707762 PMID:26990689 |
|
NCBI chrNW_004936473:29,999,542...30,034,610
Ensembl chrNW_004936473:29,999,562...30,038,293
|
|
G |
Ctsd |
cathepsin D |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:15048980 |
|
NCBI chrNW_004936816:680,798...690,959
Ensembl chrNW_004936816:680,798...691,039
|
|
G |
Ctss |
cathepsin S |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19700239 |
|
NCBI chrNW_004936580:963,176...991,732
Ensembl chrNW_004936580:963,153...991,442
|
|
G |
Ctu1 |
cytosolic thiouridylase subunit 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27811057 |
|
NCBI chrNW_004936889:728,956...735,692
Ensembl chrNW_004936889:728,362...733,141
|
|
G |
Ctu2 |
cytosolic thiouridylase subunit 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27811057 |
|
NCBI chrNW_004936641:980,493...986,015
Ensembl chrNW_004936641:980,533...984,506
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19700239 PMID:25231984 PMID:25753200 |
|
NCBI chrNW_004936617:4,224,131...4,239,080
Ensembl chrNW_004936617:4,224,131...4,238,796
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:25753200 |
|
NCBI chrNW_004936469:39,794,613...39,798,448
Ensembl chrNW_004936469:39,794,584...39,798,459
|
|
G |
Dek |
DEK proto-oncogene |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21291860 PMID:27811057 |
|
NCBI chrNW_004936552:3,964,515...3,997,318
Ensembl chrNW_004936552:3,966,198...3,993,113
|
|
G |
Dlx4 |
distal-less homeobox 4 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26213588 |
|
NCBI chrNW_004936490:11,645,787...11,650,273
Ensembl chrNW_004936490:11,645,787...11,650,273
|
|
G |
Dmd |
dystrophin |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:24793134 |
|
NCBI chrNW_004936553:7,157,526...7,943,703
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28544374 |
|
NCBI chrNW_004936659:520,181...565,496
Ensembl chrNW_004936659:520,493...565,416
|
|
G |
Ednrb |
endothelin receptor type B |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26213588 |
|
NCBI chrNW_004936511:3,446,864...3,478,434
Ensembl chrNW_004936511:3,446,839...3,478,434
|
|
G |
Eef2 |
eukaryotic translation elongation factor 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21554491 |
|
NCBI chrNW_004936588:2,259,236...2,267,692
Ensembl chrNW_004936588:2,258,309...2,266,609
|
|
G |
Egf |
epidermal growth factor |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:15802018 PMID:22869556 PMID:23064031 PMID:24587105 PMID:27634460 |
|
NCBI chrNW_004936563:1,058,803...1,181,393
|
|
G |
Egfr |
epidermal growth factor receptor |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:18844224 PMID:23867902 |
|
NCBI chrNW_004936678:365,005...560,546
Ensembl chrNW_004936678:365,834...436,528
|
|
G |
Eif4e |
eukaryotic translation initiation factor 4E |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20388789 |
|
NCBI chrNW_004936520:3,922,457...3,964,721
Ensembl chrNW_004936520:3,922,339...3,960,359
|
|
G |
Elp1 |
elongator acetyltransferase complex subunit 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27811057 |
|
NCBI chrNW_004936559:3,924,185...3,981,907
Ensembl chrNW_004936559:3,924,185...3,983,028
|
|
G |
Elp3 |
elongator acetyltransferase complex subunit 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27811057 |
|
NCBI chrNW_004936675:933,698...1,014,919
Ensembl chrNW_004936675:933,676...1,016,242
|
|
G |
En1 |
engrailed homeobox 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26213588 |
|
NCBI chrNW_004936469:51,439,944...51,451,194
|
|
G |
Eno1 |
enolase 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:15654357 |
|
NCBI chrNW_004936623:3,115,357...3,130,289
Ensembl chrNW_004936623:3,115,081...3,128,183
|
|
G |
Epas1 |
endothelial PAS domain protein 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26735578 PMID:30090327 |
|
NCBI chrNW_004936508:5,855,748...5,938,879
Ensembl chrNW_004936508:5,855,732...5,938,856
|
|
G |
Epo |
erythropoietin |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:16699298 |
|
NCBI chrNW_004936543:742,722...745,332
Ensembl chrNW_004936543:743,537...745,343
|
|
G |
Epor |
erythropoietin receptor |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:16699298 |
|
NCBI chrNW_004936659:1,468,391...1,473,880
Ensembl chrNW_004936659:1,468,634...1,473,880
|
|
G |
Eps8 |
EGFR pathway substrate 8, signaling adaptor |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19799886 |
|
NCBI chrNW_004936587:1,785,721...1,951,474
Ensembl chrNW_004936587:1,785,303...1,951,332
|
|
G |
Esr1 |
estrogen receptor 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism|therapeutic |
CTD |
PMID:26990689 PMID:27366082 PMID:35044086 |
|
NCBI chrNW_004936489:4,616,839...4,887,179
Ensembl chrNW_004936489:4,614,754...4,887,171
|
|
G |
Fam83a |
family with sequence similarity 83 member A |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:34931434 |
|
NCBI chrNW_004936470:24,119,688...24,138,413
Ensembl chrNW_004936470:24,119,636...24,138,420
|
|
G |
Fgfr4 |
fibroblast growth factor receptor 4 |
|
ISO |
ClinVar Annotator: match by term: Cancer progression and tumor cell motility |
ClinVar |
PMID:11830541 PMID:25741868 PMID:26675719 PMID:33116287 |
|
NCBI chrNW_004936597:1,388,394...1,397,731
Ensembl chrNW_004936597:1,385,624...1,397,758
|
|
G |
Fn1 |
fibronectin 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:24014025 |
|
NCBI chrNW_004936586:1,708,803...1,773,372
Ensembl chrNW_004936586:1,708,684...1,773,383
|
|
G |
Foxp1 |
forkhead box P1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:25485836 |
|
NCBI chrNW_004936603:2,631,781...3,146,104
Ensembl chrNW_004936603:2,632,274...2,830,324
|
|
G |
Fth1 |
ferritin heavy chain 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20390345 |
|
NCBI chrNW_004936581:1,118,905...1,120,592
|
|
G |
Ftl |
ferritin light chain |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20390345 |
|
NCBI chrNW_004936664:2,976,325...2,977,878
Ensembl chrNW_004936664:2,976,314...2,977,877
|
|
G |
Gab2 |
GRB2 associated binding protein 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21996746 |
|
NCBI chrNW_004936498:6,775,170...6,835,680
Ensembl chrNW_004936498:6,778,462...6,835,643
|
|
G |
Hdac3 |
histone deacetylase 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:34973135 |
|
NCBI chrNW_004936504:12,530,546...12,546,556
Ensembl chrNW_004936504:12,530,528...12,546,556
|
|
G |
Hgf |
hepatocyte growth factor |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:9932610 PMID:15654357 |
|
NCBI chrNW_004936734:354,798...428,356
Ensembl chrNW_004936734:356,115...428,779
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:12811834 PMID:29501572 |
|
NCBI chrNW_004936495:5,770,988...5,816,157
Ensembl chrNW_004936495:5,770,669...5,816,157
|
|
G |
Hmga2 |
high mobility group AT-hook 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28830677 |
|
NCBI chrNW_004936545:3,944,419...3,958,289
Ensembl chrNW_004936545:3,944,419...4,064,193
|
|
G |
Hmgcs2 |
3-hydroxy-3-methylglutaryl-CoA synthase 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27816970 |
|
NCBI chrNW_004936627:4,451,847...4,473,163
Ensembl chrNW_004936627:4,451,823...4,473,223
|
|
G |
Hmox1 |
heme oxygenase 1 |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:24211270 |
|
NCBI chrNW_004936492:5,042,353...5,049,216
Ensembl chrNW_004936492:5,042,330...5,049,311
|
|
G |
Hoxb13 |
homeobox B13 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26213588 |
|
NCBI chrNW_004936490:12,688,572...12,690,908
Ensembl chrNW_004936490:12,688,559...12,690,908
|
|
G |
Hoxb3 |
homeobox B3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:34652879 |
|
NCBI chrNW_004936490:12,834,240...12,836,812
Ensembl chrNW_004936490:12,834,240...12,836,398
|
|
G |
Hpse |
heparanase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22240343 |
|
NCBI chrNW_004936738:1,308,350...1,341,421
Ensembl chrNW_004936738:1,308,345...1,343,145
|
|
G |
Hras |
HRas proto-oncogene, GTPase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:23877152 |
|
NCBI chrNW_004936888:375,372...378,125
Ensembl chrNW_004936888:375,377...377,958
|
|
G |
Igf1 |
insulin like growth factor 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:18398872 |
|
NCBI chrNW_004936492:11,709,623...11,784,028
Ensembl chrNW_004936492:11,709,222...11,778,351
|
|
G |
Il1b |
interleukin 1 beta |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27567548 |
|
NCBI chrNW_004936783:1,251,678...1,256,807
Ensembl chrNW_004936783:1,252,158...1,257,165
|
|
G |
Il1rn |
interleukin 1 receptor antagonist |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:27567548 |
|
NCBI chrNW_004936783:1,447,158...1,466,331
Ensembl chrNW_004936783:1,447,106...1,466,340
|
|
G |
Il6 |
interleukin 6 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26101800 PMID:26284488 |
|
NCBI chrNW_004936549:7,015,595...7,016,246
|
|
G |
Ins |
insulin |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:24587105 |
|
NCBI chrNW_004936816:1,002,137...1,003,357
Ensembl chrNW_004936816:1,002,137...1,003,357
|
|
G |
Ireb2 |
iron responsive element binding protein 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20390345 |
|
NCBI chrNW_004936471:36,547,552...36,601,327
Ensembl chrNW_004936471:36,547,500...36,600,636
|
|
G |
Itga5 |
integrin subunit alpha 5 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21224397 |
|
NCBI chrNW_004936512:11,588,818...11,612,580
Ensembl chrNW_004936512:11,588,645...11,612,669
|
|
G |
Itgb1 |
integrin subunit beta 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21224397 |
|
NCBI chrNW_004936574:1,465,981...1,495,717
Ensembl chrNW_004936574:1,465,897...1,495,762
|
|
G |
Itpk1 |
inositol-tetrakisphosphate 1-kinase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26213588 |
|
NCBI chrNW_004936733:930,986...1,064,223
Ensembl chrNW_004936733:930,972...1,064,229
|
|
G |
Kcnd2 |
potassium voltage-gated channel subfamily D member 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:34418280 |
|
NCBI chrNW_004936605:4,370,222...4,828,972
Ensembl chrNW_004936605:4,372,671...4,825,423
|
|
G |
Kdm1a |
lysine demethylase 1A |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22493729 |
|
NCBI chrNW_004936474:8,262,913...8,319,089
Ensembl chrNW_004936474:8,262,885...8,319,092
|
|
G |
Krt19 |
keratin 19 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:15048980 |
|
NCBI chrNW_004936490:16,440,723...16,444,679
Ensembl chrNW_004936490:16,440,693...16,444,791
|
|
G |
Krt7 |
keratin 7 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19921857 |
|
NCBI chrNW_004936512:9,641,587...9,656,573
Ensembl chrNW_004936512:9,641,587...9,656,524
|
|
G |
Ldhb |
lactate dehydrogenase B |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:15048980 |
|
NCBI chrNW_004936548:5,224,905...5,244,708
Ensembl chrNW_004936548:5,227,666...5,244,525
|
|
G |
Lef1 |
lymphoid enhancer binding factor 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27811057 |
|
NCBI chrNW_004936818:453,635...569,194
Ensembl chrNW_004936818:453,635...567,469
|
|
G |
Lin28a |
lin-28 homolog A |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26910839 |
|
NCBI chrNW_004936474:10,896,153...10,909,247
|
|
G |
LOC101964975 |
interleukin-8 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:32512068 |
|
NCBI chrNW_004936598:1,779,471...1,781,353
Ensembl chrNW_004936598:1,779,471...1,781,353
|
|
G |
LOC101965998 |
notch receptor 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:30670679 |
|
NCBI chrNW_004936872:454,273...539,544
Ensembl chrNW_004936872:390,852...536,321
|
|
G |
LOC101970831 |
serotransferrin |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20390345 |
|
NCBI chrNW_004936529:6,917,762...6,947,512
Ensembl chrNW_004936529:6,855,958...6,947,394
|
|
G |
LOC101973029 |
cytochrome P450 2E1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26213588 |
|
NCBI chrNW_004936486:19,691,822...19,702,684
Ensembl chrNW_004936486:19,691,822...19,702,102
|
|
G |
LOC110599509 |
uncharacterized LOC110599509 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26213588 |
|
NCBI chrNW_004936721:1,347,679...1,350,598
|
|
G |
Loxl2 |
lysyl oxidase like 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:24014025 |
|
NCBI chrNW_004936555:6,781,563...6,865,662
Ensembl chrNW_004936555:6,781,321...6,865,768
|
|
G |
Mapk1 |
mitogen-activated protein kinase 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22580338 |
|
NCBI chrNW_004936619:1,889,841...1,932,646
Ensembl chrNW_004936619:1,889,708...1,932,646
|
|
G |
Mapk3 |
mitogen-activated protein kinase 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22580338 |
|
NCBI chrNW_004936501:12,342,670...12,390,650
Ensembl chrNW_004936501:12,384,804...12,392,180
|
|
G |
Met |
MET proto-oncogene, receptor tyrosine kinase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:15654357 |
|
NCBI chrNW_004936589:2,280,803...2,390,179
Ensembl chrNW_004936589:2,280,799...2,390,179
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22580338 |
|
NCBI chrNW_004936551:5,167,909...5,175,149
Ensembl chrNW_004936551:5,168,044...5,174,857
|
|
G |
Mmp14 |
matrix metallopeptidase 14 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:24014025 |
|
NCBI chrNW_004936722:1,447,189...1,457,632
Ensembl chrNW_004936722:1,447,335...1,457,611
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:18398872 PMID:19770485 PMID:22321834 PMID:23707804 PMID:34278709 |
|
NCBI chrNW_004936475:7,801,356...7,825,831
Ensembl chrNW_004936475:7,801,277...7,825,851
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19617202 PMID:19700239 PMID:20188714 PMID:21187089 PMID:22503731 PMID:23867902 PMID:24333868 More...
|
|
NCBI chrNW_004936514:7,038,240...7,045,873
Ensembl chrNW_004936514:7,037,639...7,045,793
|
|
G |
Mt3 |
metallothionein 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:23794209 |
|
NCBI chrNW_004936475:8,864,512...8,866,516
Ensembl chrNW_004936475:8,864,675...8,866,506
|
|
G |
Mtdh |
metadherin |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:29315995 |
|
NCBI chrNW_004936470:45,016,099...45,079,709
Ensembl chrNW_004936470:45,016,099...45,079,710
|
|
G |
Myd88 |
MYD88 innate immune signal transduction adaptor |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21473897 |
|
NCBI chrNW_004936473:27,672,237...27,676,339
Ensembl chrNW_004936473:27,671,797...27,676,372
|
|
G |
Myh9 |
myosin heavy chain 9 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28650484 |
|
NCBI chrNW_004936492:4,384,215...4,466,229
Ensembl chrNW_004936492:4,384,215...4,466,262
|
|
G |
Mylk |
myosin light chain kinase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:10232591 PMID:12970723 |
|
NCBI chrNW_004936725:1,418,930...1,594,697
Ensembl chrNW_004936725:1,424,130...1,592,840
|
|
G |
Ncam1 |
neural cell adhesion molecule 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19700239 |
|
NCBI chrNW_004936612:1,262,557...1,556,281
Ensembl chrNW_004936612:1,262,544...1,556,016
|
|
G |
Nek2 |
NIMA related kinase 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28509438 |
|
NCBI chrNW_004936557:1,683,027...1,695,410
Ensembl chrNW_004936557:1,682,984...1,695,414
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:32682831 |
|
NCBI chrNW_004936509:6,589,967...6,621,171
Ensembl chrNW_004936509:6,590,630...6,620,262
|
|
G |
Nrg1 |
neuregulin 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19617202 |
|
NCBI chrNW_004936766:1,104,841...1,306,368
Ensembl chrNW_004936766:1,104,728...1,305,972
|
|
G |
Nuak1 |
NUAK family kinase 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26213588 PMID:26873845 |
|
NCBI chrNW_004936492:8,710,039...8,774,870
Ensembl chrNW_004936492:8,710,039...8,775,112
|
|
G |
Pak1 |
p21 (RAC1) activated kinase 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:35066776 |
|
NCBI chrNW_004936498:6,001,126...6,135,663
Ensembl chrNW_004936498:6,001,014...6,086,614
|
|
G |
Pax6 |
paired box 6 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26213588 |
|
NCBI chrNW_004936533:5,952,529...5,980,889
Ensembl chrNW_004936533:5,957,971...5,982,075
|
|
G |
Pdcd4 |
programmed cell death 4 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:23272133 |
|
NCBI chrNW_004936486:1,684,167...1,705,387
Ensembl chrNW_004936486:1,684,135...1,705,715
|
|
G |
Pip5k1a |
phosphatidylinositol-4-phosphate 5-kinase type 1 alpha |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:34755307 |
|
NCBI chrNW_004936580:1,399,492...1,448,398
Ensembl chrNW_004936580:1,399,954...1,446,769
|
|
G |
Pkm |
pyruvate kinase M1/2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:15048980 PMID:15654357 |
|
NCBI chrNW_004936471:31,589,322...31,617,891
Ensembl chrNW_004936471:31,589,324...31,617,873
|
|
G |
Plau |
plasminogen activator, urokinase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:14644129 PMID:26284488 |
|
NCBI chrNW_004936521:5,238,128...5,243,829
Ensembl chrNW_004936521:5,238,093...5,243,877
|
|
G |
Plaur |
plasminogen activator, urokinase receptor |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD RGD |
PMID:12198772 PMID:22261521 |
RGD:729319 |
NCBI chrNW_004936706:840,968...855,552
|
|
G |
Ppp1r12b |
protein phosphatase 1 regulatory subunit 12B |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28650484 |
|
NCBI chrNW_004936567:1,992,487...2,208,611
Ensembl chrNW_004936567:1,992,495...2,208,684
|
|
G |
Prdx2 |
peroxiredoxin 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:23911960 |
|
NCBI chrNW_004936659:1,894,423...1,897,690
|
|
G |
Pten |
phosphatase and tensin homolog |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:21994956 |
|
NCBI chrNW_004936735:1,252,414...1,338,318
Ensembl chrNW_004936735:1,252,414...1,338,323
|
|
G |
Ptk2 |
protein tyrosine kinase 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism|therapeutic |
CTD |
PMID:12811834 PMID:25199511 |
|
NCBI chrNW_004936470:10,379,855...10,578,531
Ensembl chrNW_004936470:10,379,872...10,578,543
|
|
G |
Rab27a |
RAB27A, member RAS oncogene family |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:34291859 |
|
NCBI chrNW_004936471:16,738,204...16,815,561
Ensembl chrNW_004936471:16,738,230...16,815,943
|
|
G |
Rab27b |
RAB27B, member RAS oncogene family |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:34291859 |
|
NCBI chrNW_004936497:9,039,552...9,176,182
Ensembl chrNW_004936497:9,039,546...9,098,039
|
|
G |
Rasal2 |
RAS protein activator like 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:34826200 |
|
NCBI chrNW_004936481:10,358,673...10,688,535
Ensembl chrNW_004936481:10,365,303...10,688,578
|
|
G |
Rbm38 |
RNA binding motif protein 38 |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:34453780 |
|
NCBI chrNW_004936530:227,266...249,285
|
|
G |
Reck |
reversion inducing cysteine rich protein with kazal motifs |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:20127710 |
|
NCBI chrNW_004936524:4,021,666...4,099,703
Ensembl chrNW_004936524:4,021,660...4,099,705
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19896475 PMID:29501572 |
|
NCBI chrNW_004936599:3,800,142...3,810,583
Ensembl chrNW_004936599:3,801,636...3,809,813
|
|
G |
Rhoa |
ras homolog family member A |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19896475 |
|
NCBI chrNW_004936529:1,000,050...1,045,655
Ensembl chrNW_004936529:999,935...1,045,681
|
|
G |
Rnf207 |
ring finger protein 207 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26213588 |
|
NCBI chrNW_004936623:1,065,260...1,079,918
Ensembl chrNW_004936623:1,066,957...1,079,030
|
|
G |
Rpl3l |
ribosomal protein L3 like |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26213588 |
|
NCBI chrNW_004936694:2,078,903...2,086,333
Ensembl chrNW_004936694:2,078,903...2,086,354
|
|
G |
Rps6ka3 |
ribosomal protein S6 kinase A3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21488662 |
|
NCBI chrNW_004936624:3,897,878...4,005,664
Ensembl chrNW_004936624:3,897,791...4,000,558
|
|
G |
Rpsa |
ribosomal protein SA |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:15048980 |
|
NCBI chrNW_004936473:28,624,110...28,628,488
|
|
G |
S100a4 |
S100 calcium binding protein A4 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:15048980 |
|
NCBI chrNW_004936580:3,355,751...3,358,030
Ensembl chrNW_004936580:3,355,699...3,358,242
|
|
G |
S1pr2 |
sphingosine-1-phosphate receptor 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26518876 |
|
NCBI chrNW_004936659:579,771...587,077
Ensembl chrNW_004936659:579,867...586,885
|
|
G |
Septin9 |
septin 9 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20388789 |
|
NCBI chrNW_004936594:2,213,459...2,286,582
|
|
G |
Set |
SET nuclear proto-oncogene |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:24555657 |
|
NCBI chrNW_004936487:16,181,764...16,184,706
|
|
G |
Slc39a10 |
solute carrier family 39 member 10 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:17359283 |
|
NCBI chrNW_004936506:3,298,259...3,425,126
Ensembl chrNW_004936506:3,298,245...3,396,291
|
|
G |
Slc6a12 |
solute carrier family 6 member 12 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26213588 |
|
NCBI chrNW_004936606:387,342...412,684
Ensembl chrNW_004936606:384,124...411,698
|
|
G |
Smpd1 |
sphingomyelin phosphodiesterase 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:24951586 |
|
NCBI chrNW_004936842:448,315...452,557
Ensembl chrNW_004936842:447,991...452,630
|
|
G |
Snai1 |
snail family transcriptional repressor 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22580338 PMID:24014025 |
|
NCBI chrNW_004936514:4,456,498...4,462,436
Ensembl chrNW_004936514:4,456,484...4,462,987
|
|
G |
Snai2 |
snail family transcriptional repressor 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22580338 |
|
NCBI chrNW_004936590:3,813,916...3,817,642
Ensembl chrNW_004936590:3,813,888...3,817,642
|
|
G |
Sod2 |
superoxide dismutase 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:10853026 PMID:11053990 PMID:15048980 PMID:15654357 PMID:21749277 PMID:22580338 More...
|
|
NCBI chrNW_004936489:11,178,338...11,191,601
Ensembl chrNW_004936489:11,178,015...11,191,781
|
|
G |
Sorl1 |
sortilin related receptor 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26213588 |
|
NCBI chrNW_004936542:6,192,407...6,352,835
Ensembl chrNW_004936542:6,192,407...6,352,424
|
|
G |
Sox11 |
SRY-box transcription factor 11 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26213588 |
|
NCBI chrNW_004937107:203,120...207,185
|
|
G |
Sox9 |
SRY-box transcription factor 9 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:32682831 |
|
NCBI chrNW_004936655:1,849,044...1,852,648
Ensembl chrNW_004936655:1,847,272...1,852,705
|
|
G |
Sp1 |
Sp1 transcription factor |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26317792 PMID:35072892 |
|
NCBI chrNW_004936512:10,655,116...10,693,025
Ensembl chrNW_004936512:10,655,349...10,693,042
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:18844224 PMID:21291860 |
|
NCBI chrNW_004936561:3,826,802...3,844,406
Ensembl chrNW_004936561:3,825,787...3,844,483
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26101800 |
|
NCBI chrNW_004936490:17,119,189...17,178,402
Ensembl chrNW_004936490:17,117,290...17,178,402
|
|
G |
Sumo1 |
small ubiquitin like modifier 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:15048980 |
|
NCBI chrNW_004936726:1,402,977...1,413,974
Ensembl chrNW_004936726:1,399,050...1,429,205
|
|
G |
Tbx15 |
T-box transcription factor 15 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26213588 |
|
NCBI chrNW_004936627:3,745,399...3,852,861
Ensembl chrNW_004936627:3,745,287...3,853,309
|
|
G |
Tfpi2 |
tissue factor pathway inhibitor 2 |
|
ISO |
|
RGD |
PMID:11687973 |
RGD:11060269 |
NCBI chrNW_004936803:69,296...90,270
Ensembl chrNW_004936803:73,946...90,295
|
|
G |
Tgfb1 |
transforming growth factor beta 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:23992306 PMID:24727557 PMID:24793912 PMID:25884904 PMID:26896736 PMID:32745479 More...
|
|
NCBI chrNW_004936661:3,742,080...3,758,266
Ensembl chrNW_004936661:3,742,066...3,758,272
|
|
G |
Tgif1 |
TGFB induced factor homeobox 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:25791921 |
|
NCBI chrNW_004936672:1,128,104...1,135,844
Ensembl chrNW_004936672:1,128,108...1,136,292
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:1318976 |
|
NCBI chrNW_004936502:13,345,936...13,350,170
Ensembl chrNW_004936502:13,345,832...13,350,248
|
|
G |
Timp3 |
TIMP metallopeptidase inhibitor 3 |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:23109338 |
|
NCBI chrNW_004936492:6,996,627...7,046,137
Ensembl chrNW_004936492:6,996,613...7,046,190
|
|
G |
Tkt |
transketolase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:15654357 |
|
NCBI chrNW_004936473:3,950,846...3,978,778
Ensembl chrNW_004936473:3,950,920...3,978,672
|
|
G |
Tln1 |
talin 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21291860 |
|
NCBI chrNW_004936524:3,693,679...3,727,055
Ensembl chrNW_004936524:3,693,679...3,727,098
|
|
G |
Tlr4 |
toll like receptor 4 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21473897 |
|
NCBI chrNW_004936487:6,519,140...6,532,018
Ensembl chrNW_004936487:6,518,441...6,533,095
|
|
G |
Tmem139 |
transmembrane protein 139 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26213588 |
|
NCBI chrNW_004936527:736,173...739,142
Ensembl chrNW_004936527:736,085...739,173
|
|
G |
Tnf |
tumor necrosis factor |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22199285 PMID:23431386 PMID:23899529 PMID:24613819 |
|
NCBI chrNW_004936727:1,936,066...1,937,766
Ensembl chrNW_004936727:1,936,066...1,937,766
|
|
G |
Tp53bp2 |
tumor protein p53 binding protein 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28650484 |
|
NCBI chrNW_004936526:936,981...1,000,070
Ensembl chrNW_004936526:936,359...1,000,076
|
|
G |
Trim47 |
tripartite motif containing 47 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:31981573 |
|
NCBI chrNW_004936594:1,049,308...1,053,533
Ensembl chrNW_004936594:1,049,470...1,053,515
|
|
G |
Trpm7 |
transient receptor potential cation channel subfamily M member 7 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:30710498 |
|
NCBI chrNW_004936471:12,564,617...12,666,229
Ensembl chrNW_004936471:12,565,054...12,665,962
|
|
G |
Twist1 |
twist family bHLH transcription factor 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22155737 |
|
NCBI chrNW_004936546:5,331,220...5,332,669
Ensembl chrNW_004936546:5,331,863...5,332,555
|
|
G |
Txn |
thioredoxin |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:15048980 |
|
NCBI chrNW_004936559:2,811,786...2,822,528
Ensembl chrNW_004936559:2,811,782...2,822,528
|
|
G |
Ubqln1 |
ubiquilin 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:24747970 |
|
NCBI chrNW_004936828:543,651...588,673
Ensembl chrNW_004936828:542,407...588,679
|
|
G |
Vim |
vimentin |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27811057 |
|
NCBI chrNW_004936520:10,051,692...10,059,324
Ensembl chrNW_004936520:10,052,012...10,059,182
|
|
G |
Xpc |
XPC complex subunit, DNA damage recognition and repair factor |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27777383 |
|
NCBI chrNW_004936602:118,173...139,884
Ensembl chrNW_004936602:118,188...139,675
|
|
G |
Xrcc3 |
X-ray repair cross complementing 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21283680 |
|
NCBI chrNW_004936621:1,462,441...1,474,937
Ensembl chrNW_004936621:1,462,428...1,473,868
|
|
G |
Yap1 |
Yes1 associated transcriptional regulator |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:34351699 |
|
NCBI chrNW_004936551:5,638,383...5,740,523
Ensembl chrNW_004936551:5,634,751...5,740,567
|
|
G |
Zbtb16 |
zinc finger and BTB domain containing 16 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26213588 |
|
NCBI chrNW_004936612:389,877...570,595
Ensembl chrNW_004936612:395,177...570,595
|
|
G |
Zeb1 |
zinc finger E-box binding homeobox 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21954225 |
|
NCBI chrNW_004936574:17,643...175,762
Ensembl chrNW_004936574:17,684...178,293
|
|
G |
Zeb2 |
zinc finger E-box binding homeobox 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21954225 |
|
NCBI chrNW_004936469:32,240,730...32,372,413
Ensembl chrNW_004936469:32,240,835...32,371,267
|
|
G |
Zfp36 |
ZFP36 ring finger protein |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:25556371 |
|
NCBI chrNW_004936661:2,251,148...2,253,527
Ensembl chrNW_004936661:2,250,665...2,253,787
|
|
G |
Zfr |
zinc finger RNA binding protein |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:34323000 |
|
NCBI chrNW_004936518:8,367,396...8,442,271
Ensembl chrNW_004936518:8,367,479...8,440,851
|
|
G |
Znf367 |
zinc finger protein 367 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:34351699 |
|
NCBI chrNW_004936487:333,952...347,465
Ensembl chrNW_004936487:336,218...346,869
|
|
|
G |
Abcb1 |
ATP binding cassette subfamily B member 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:12015757 |
|
NCBI chrNW_004936763:1,225,355...1,308,257
Ensembl chrNW_004936763:1,226,482...1,297,427
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 (PEL blood group) |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:17003774 |
|
NCBI chrNW_004936472:14,396,986...14,624,597
Ensembl chrNW_004936472:14,397,222...14,624,648
|
|
G |
Ackr3 |
atypical chemokine receptor 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22180778 |
|
NCBI chrNW_004936525:1,559,575...1,570,679
|
|
G |
Acsbg1 |
acyl-CoA synthetase bubblegum family member 1 |
|
ISO |
associated with pheochromocytoma |
RGD |
PMID:29067245 |
RGD:13831131 |
NCBI chrNW_004936471:36,767,656...36,822,677
Ensembl chrNW_004936471:36,767,652...36,822,722
|
|
G |
Acvr2a |
activin A receptor type 2A |
exacerbates |
ISO |
associated with colon cancer;mRNA,protein:decreased expression:colon (human) |
RGD |
PMID:30310521 |
RGD:151361136 |
NCBI chrNW_004936469:29,195,329...29,273,237
Ensembl chrNW_004936469:29,194,908...29,273,196
|
|
G |
Adora2b |
adenosine A2b receptor |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27590504 |
|
NCBI chrNW_004936821:583,463...608,189
Ensembl chrNW_004936821:580,675...608,245
|
|
G |
Agtr1 |
angiotensin II receptor type 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:18059164 |
|
NCBI chrNW_004936519:6,831,096...6,873,977
Ensembl chrNW_004936519:6,831,096...6,873,985
|
|
G |
Agtr2 |
angiotensin II receptor type 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:18059164 |
|
NCBI chrNW_004936479:13,252,678...13,255,570
Ensembl chrNW_004936479:13,252,678...13,255,570
|
|
G |
Ahr |
aryl hydrocarbon receptor |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:21948867 |
|
NCBI chrNW_004936546:3,737,908...3,783,492
Ensembl chrNW_004936546:3,737,851...3,783,588
|
|
G |
Akirin2 |
akirin 2 |
|
ISO |
|
RGD |
PMID:18460465 |
RGD:2306009 |
NCBI chrNW_004936510:4,216,893...4,221,962
Ensembl chrNW_004936510:4,216,955...4,221,962
|
|
G |
Akt2 |
AKT serine/threonine kinase 2 |
|
ISO |
associated with Mammary Neoplasms, Experimental |
RGD |
PMID:19491266 |
RGD:2315599 |
NCBI chrNW_004936661:2,652,568...2,694,039
Ensembl chrNW_004936661:2,652,566...2,694,086
|
|
G |
Alk |
ALK receptor tyrosine kinase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22986231 PMID:22999080 |
|
NCBI chrNW_004936493:3,624,288...3,671,567
Ensembl chrNW_004936493:3,028,608...3,671,874
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20061081 |
|
NCBI chrNW_004936554:7,807,914...7,848,691
Ensembl chrNW_004936554:7,808,355...7,867,931
|
|
G |
Amigo2 |
adhesion molecule with Ig like domain 2 |
|
ISO |
Liver Metastasis |
RGD |
PMID:28272394 |
RGD:14394499 |
NCBI chrNW_004936512:5,157,076...5,160,251
Ensembl chrNW_004936512:5,157,175...5,159,818
|
|
G |
Angptl4 |
angiopoietin like 4 |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:17130448 |
|
NCBI chrNW_004936588:5,188,866...5,194,924
Ensembl chrNW_004936588:5,188,850...5,194,931
|
|
G |
Antxr1 |
ANTXR cell adhesion molecule 1 |
|
ISO |
associated with Mammary Neoplasms, Experimental; |
RGD |
PMID:22085271 |
RGD:9684855 |
NCBI chrNW_004936491:13,288,986...13,516,878
Ensembl chrNW_004936491:13,288,717...13,516,984
|
|
G |
Anxa1 |
annexin A1 |
treatment |
ISO |
associated with Mammary Neoplasms, Experimental associated with Mammary Neoplasms, Experimental;protein:increased expression:lung CTD Direct Evidence: marker/mechanism |
RGD CTD |
PMID:9514092 PMID:20308542 PMID:20821804 |
RGD:2306939 RGD:7421541 RGD:7421563 |
NCBI chrNW_004936503:9,124,314...9,142,372
Ensembl chrNW_004936503:9,124,264...9,142,413
|
|
G |
Anxa4 |
annexin A4 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:17085005 |
|
NCBI chrNW_004936491:13,982,926...14,047,690
Ensembl chrNW_004936491:13,982,677...14,047,690
|
|
G |
Anxa7 |
annexin A7 |
|
ISO |
associated with Breast Neoplasms;protein:increased expression:breast associated with Prostatic Neoplasms;protein:decreased expression:prostate gland |
RGD |
PMID:11287641 PMID:15073110 |
RGD:2292655 RGD:2292656 |
NCBI chrNW_004936521:5,639,193...5,671,369
Ensembl chrNW_004936521:5,651,719...5,671,050
|
|
G |
Apoe |
apolipoprotein E |
|
ISO |
|
RGD |
PMID:22469977 |
RGD:7771597 |
NCBI chrNW_004936706:1,512,438...1,516,805
|
|
G |
Arhgdia |
Rho GDP dissociation inhibitor alpha |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20562527 |
|
NCBI chrNW_004936594:5,383,370...5,386,618
Ensembl chrNW_004936594:5,383,380...5,386,494
|
|
G |
Arid1a |
AT-rich interaction domain 1A |
disease_progression |
ISO |
in lung; associated with hepatocellular carcinoma |
RGD |
PMID:25975202 |
RGD:125097495 |
NCBI chrNW_004936474:11,148,857...11,197,312
|
|
G |
Atp6v1c1 |
ATPase H+ transporting V1 subunit C1 |
|
ISO |
associated with Mammary Neoplasms, Experimental |
RGD |
PMID:24155661 |
RGD:14700647 |
NCBI chrNW_004936470:40,626,523...40,675,435
Ensembl chrNW_004936470:40,623,553...40,675,598
|
|
G |
Axl |
AXL receptor tyrosine kinase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26206560 |
|
NCBI chrNW_004936661:3,658,140...3,687,290
Ensembl chrNW_004936661:3,657,831...3,687,816
|
|
G |
Azin1 |
antizyme inhibitor 1 |
|
ISO |
associated with colorectal cancer;RNA:increased editing:colorectum associated with stomach cancer;RNA:increased editing:stomach |
RGD |
PMID:29925690 PMID:30563560 |
RGD:14700703 RGD:14700704 |
NCBI chrNW_004936470:40,801,943...40,832,543
Ensembl chrNW_004936470:40,801,943...40,834,003
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
|
ISO |
associated with Carcinoma, Infiltrating Duct |
RGD |
PMID:17288732 |
RGD:1643356 |
NCBI chrNW_004936664:2,968,103...2,973,652
Ensembl chrNW_004936664:2,967,865...2,973,820
|
|
G |
Bcl2 |
BCL2 apoptosis regulator |
|
ISO |
associated with Carcinoma, Renal Cell associated with Breast Neoplasms |
RGD |
PMID:12810203 PMID:16826579 |
RGD:2293020 RGD:2293021 |
NCBI chrNW_004936497:2,209,136...2,373,580
Ensembl chrNW_004936497:2,210,334...2,210,921
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
severity |
ISO |
associated with Prostatic Neoplasms;protein:increased expression:bone |
RGD |
PMID:16166304 |
RGD:2289018 |
NCBI chrNW_004936534:4,707,658...4,871,865
Ensembl chrNW_004936534:4,709,064...4,871,023
|
|
G |
Bmp7 |
bone morphogenetic protein 7 |
disease_progression |
ISO |
associated with Prostatic Neoplasms;mRNA:increased expression:bone associated with Breast Neoplasms;protein:increased expression:breast |
RGD |
PMID:12539225 PMID:17895257 |
RGD:2289029 RGD:2289033 |
NCBI chrNW_004936530:71,965...143,940
Ensembl chrNW_004936530:71,920...143,940
|
|
G |
Braf |
B-Raf proto-oncogene, serine/threonine kinase |
onset |
ISO |
associated with Melanoma; DNA:mutations: : |
RGD |
PMID:25623140 |
RGD:11567259 |
NCBI chrNW_004936592:4,728,371...4,833,830
Ensembl chrNW_004936592:4,737,011...4,834,664
|
|
G |
Brd4 |
bromodomain containing 4 |
|
ISO |
|
RGD |
PMID:23950209 |
RGD:9586346 |
NCBI chrNW_004936596:5,176,682...5,246,102
Ensembl chrNW_004936596:5,177,147...5,246,518
|
|
G |
Brms1 |
BRMS1 transcriptional repressor and anoikis regulator |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:27501413 |
|
NCBI chrNW_004936599:3,259,868...3,267,172
Ensembl chrNW_004936599:3,259,835...3,267,676
|
|
G |
Bsg |
basigin (Ok blood group) |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21956400 |
|
NCBI chrNW_004936588:181,688...189,795
Ensembl chrNW_004936588:181,576...189,287
|
|
G |
Cab39 |
calcium binding protein 39 |
|
ISO |
associated with hepatocellular carcinoma; |
RGD |
PMID:28605041 |
RGD:14398832 |
NCBI chrNW_004936525:5,955,252...6,002,917
Ensembl chrNW_004936525:5,954,978...6,032,644
|
|
G |
Cacybp |
calcyclin binding protein |
|
ISO |
associated with pancreatic neoplasms |
RGD |
PMID:18765951 |
RGD:2326146 |
NCBI chrNW_004936481:13,198,744...13,203,518
|
|
G |
Cap1 |
cyclase associated actin cytoskeleton regulatory protein 1 |
|
ISO |
associated with Pancreatic Neoplasms; mRNA, protein:increased expression:pancreas |
RGD |
PMID:19188911 |
RGD:2326238 |
NCBI chrNW_004936474:21,854,454...21,881,622
Ensembl chrNW_004936474:21,854,330...21,881,622
|
|
G |
Casp3 |
caspase 3 |
|
ISO |
associated with Breast Neoplasms |
RGD |
PMID:18064531 |
RGD:2293306 |
NCBI chrNW_004936554:4,571,072...4,593,765
|
|
G |
Cat |
catalase |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:12538496 PMID:22580338 PMID:23518002 |
|
NCBI chrNW_004936533:3,601,270...3,637,128
Ensembl chrNW_004936533:3,600,955...3,637,422
|
|
G |
Cav1 |
caveolin 1 |
treatment |
ISO |
CTD Direct Evidence: marker/mechanism associated with Mammary Neoplasms, Experimental |
CTD RGD |
PMID:15334058 PMID:15355971 PMID:20562527 |
RGD:2289106 RGD:8661780 |
NCBI chrNW_004936589:2,504,235...2,536,778
Ensembl chrNW_004936589:2,504,224...2,537,170
|
|
G |
Cbx4 |
chromobox 4 |
|
ISO |
associated with Carcinoma, Hepatocellular; |
RGD |
PMID:24838576 |
RGD:9586738 |
NCBI chrNW_004936594:3,943,933...3,950,124
Ensembl chrNW_004936594:3,943,924...3,950,196
|
|
G |
Cbx5 |
chromobox 5 |
|
ISO |
associated with Lung Neoplasms; |
RGD |
PMID:22900142 |
RGD:9586743 |
NCBI chrNW_004936512:11,441,770...11,480,924
Ensembl chrNW_004936512:11,450,060...11,480,727
|
|
G |
Ccl20 |
C-C motif chemokine ligand 20 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:30603057 |
|
NCBI chrNW_004936525:8,238,128...8,240,974
Ensembl chrNW_004936525:8,237,831...8,240,974
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
treatment |
ISO |
associated with Animal Mammary Neoplasms; |
RGD |
PMID:15692764 |
RGD:14995455 |
NCBI chrNW_004936490:253,279...259,947
Ensembl chrNW_004936490:253,034...259,965
|
|
G |
Ccn4 |
cellular communication network factor 4 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:30723155 |
|
NCBI chrNW_004936470:16,110,492...16,134,065
Ensembl chrNW_004936470:16,110,497...16,134,065
|
|
G |
Ccna2 |
cyclin A2 |
|
ISO |
associated with Seminoma;protein:increased expression:testis |
RGD |
PMID:14696091 |
RGD:2293346 |
NCBI chrNW_004936662:1,073,460...1,079,136
Ensembl chrNW_004936662:1,073,920...1,079,136
|
|
G |
Ccnd1 |
cyclin D1 |
treatment |
ISO |
associated with Carcinoma, Non-Small-Cell Lung;mRNA:splice variant associated with stomach cancer; human cells in mouse model |
RGD |
PMID:18715616 PMID:27431311 |
RGD:13434926 RGD:152995400 |
Ensembl chrNW_004936599:973,838...983,316
|
|
G |
Ccnd2 |
cyclin D2 |
|
ISO |
associated with Breast Neoplasms;DNA:hypermethylated:brain |
RGD |
PMID:15131050 |
RGD:2289155 |
NCBI chrNW_004936606:4,474,801...4,496,158
Ensembl chrNW_004936606:4,474,749...4,496,810
|
|
G |
Ccne1 |
cyclin E1 |
disease_progression |
ISO |
protein:altered processing associated with non-small cell lung carcinoma |
RGD |
PMID:11212263 PMID:17671189 |
RGD:13673913 RGD:2289229 |
NCBI chrNW_004936570:5,536,817...5,547,880
Ensembl chrNW_004936570:5,536,672...5,548,008
|
|
G |
Cd274 |
CD274 molecule |
disease_progression |
ISO |
associated with ovarian cancer |
RGD |
PMID:23340297 |
RGD:41410797 |
NCBI chrNW_004936539:132,870...145,288
Ensembl chrNW_004936539:132,868...143,602
|
|
G |
Cd44 |
CD44 molecule (IN blood group) |
|
ISO |
associated with Carcinoma, Renal Cell;protein:increased expression:kidney CTD Direct Evidence: marker/mechanism |
RGD CTD |
PMID:18026989 PMID:23098472 |
RGD:2289347 |
NCBI chrNW_004936533:2,949,026...3,033,166
|
|
G |
Cd82 |
CD82 molecule |
|
ISO |
associated with Prostatic Neoplasms;mRNA:decreased expression:bone associated with Carcinoma, Hepatocellular;mRNA:decreased expression associated with Prostatic Neoplasms;DNA:loss of heterozygosity associated with Carcinoma, Infiltrating Duct;mRNA:decreased expression:brain CTD Direct Evidence: therapeutic |
RGD CTD |
PMID:9254900 PMID:9831222 PMID:11275982 PMID:12806379 PMID:15592684 PMID:20075392 More...
|
RGD:2289400 RGD:2289402 RGD:2289407 RGD:2289425 RGD:68869 |
|
|
G |
Cd86 |
CD86 molecule |
|
ISO |
mRNA:decreased expression:mediastinal lymph node (rat) |
RGD |
PMID:18360875 |
RGD:4892237 |
NCBI chrNW_004936536:8,414,491...8,481,712
|
|
G |
Cdh1 |
cadherin 1 |
treatment |
ISO |
associated with Prostatic Neoplasms associated with stomach cancer; human cells in mouse model CTD Direct Evidence: marker/mechanism |
RGD CTD |
PMID:17520682 PMID:18008331 PMID:22580338 PMID:27431311 |
RGD:152995400 RGD:2289488 |
NCBI chrNW_004936475:18,990,529...19,065,954
Ensembl chrNW_004936475:18,990,474...19,067,203
|
|
G |
Cdh2 |
cadherin 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:23876460 |
|
NCBI chrNW_004936550:6,885,484...7,067,001
Ensembl chrNW_004936550:6,886,706...6,945,056
|
|
G |
Cdkl2 |
cyclin dependent kinase like 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:25333262 |
|
NCBI chrNW_004936598:337,701...377,091
Ensembl chrNW_004936598:339,384...377,728
|
|
G |
Cdkn1a |
cyclin dependent kinase inhibitor 1A |
|
ISO |
associated with Melanoma; |
RGD |
PMID:9194578 |
RGD:8662817 |
NCBI chrNW_004936476:22,717,308...22,725,127
Ensembl chrNW_004936476:22,717,260...22,725,182
|
|
G |
Cfl1 |
cofilin 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20562527 |
|
NCBI chrNW_004936599:3,678,724...3,682,314
Ensembl chrNW_004936599:3,677,804...3,682,307
|
|
G |
Cga |
glycoprotein hormones, alpha polypeptide |
|
ISO |
associated with Breast Neoplasms;protein:increased expression:serum |
RGD |
PMID:6768680 |
RGD:2293637 |
NCBI chrNW_004936510:4,679,349...4,696,511
Ensembl chrNW_004936510:4,679,321...4,696,529
|
|
G |
Chek1 |
checkpoint kinase 1 |
|
ISO |
associated with Pancreatic Neoplasms |
RGD |
PMID:15448002 |
RGD:2317235 |
NCBI chrNW_004936743:2,004,535...2,027,287
Ensembl chrNW_004936743:2,005,851...2,026,587
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
|
ISO |
associated with prostate adenocarcinoma |
RGD |
PMID:17377533 |
RGD:2298657 |
NCBI chrNW_004936636:33,933...78,990
Ensembl chrNW_004936636:33,673...79,194
|
|
G |
Cic |
capicua transcriptional repressor |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27869830 |
|
NCBI chrNW_004936706:216,394...243,361
Ensembl chrNW_004936706:212,833...242,756
|
|
G |
Cldn7 |
claudin 7 |
|
ISO |
|
RGD |
PMID:23390083 |
RGD:9685143 |
NCBI chrNW_004936595:550,359...552,214
Ensembl chrNW_004936595:550,568...552,632
|
|
G |
Clic1 |
chloride intracellular channel 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20562527 |
|
NCBI chrNW_004936727:1,797,966...1,803,401
Ensembl chrNW_004936727:1,797,966...1,803,401
|
|
G |
Clu |
clusterin |
|
ISO |
associated with Breast Neoplasms |
RGD |
PMID:20307318 |
RGD:8883512 |
NCBI chrNW_004936675:499,745...513,515
Ensembl chrNW_004936675:499,199...513,836
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:29179997 |
|
NCBI chrNW_004936631:3,721,307...3,785,346
Ensembl chrNW_004936631:3,721,313...3,780,892
|
|
G |
Csf1 |
colony stimulating factor 1 |
|
ISO |
associated with Prostatic Neoplasms |
RGD |
PMID:18510570 |
RGD:2293638 |
NCBI chrNW_004936704:1,372,137...1,393,355
Ensembl chrNW_004936704:1,378,103...1,393,542
|
|
G |
Csf1r |
colony stimulating factor 1 receptor |
exacerbates |
ISO |
associated with Prostatic Neoplasms associated with breast cancer CTD Direct Evidence: marker/mechanism |
RGD CTD |
PMID:1390197 PMID:18510570 PMID:25005824 |
RGD:150524287 RGD:2293638 |
NCBI chrNW_004936504:4,898,947...4,927,195
Ensembl chrNW_004936504:4,898,945...4,928,923
|
|
G |
Csf3 |
colony stimulating factor 3 |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:7543699 PMID:9018096 |
|
NCBI chrNW_004936490:15,142,526...15,146,375
Ensembl chrNW_004936490:15,142,808...15,144,487
|
|
G |
Csta |
cystatin A |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20461718 |
|
NCBI chrNW_004936536:8,649,890...8,662,472
Ensembl chrNW_004936536:8,649,703...8,662,490
|
|
G |
Ctla4 |
cytotoxic T-lymphocyte associated protein 4 |
disease_progression |
ISO |
associated with Mammary Neoplasms, Experimental |
RGD |
PMID:15701862 PMID:18049334 |
RGD:4891518 RGD:7204722 |
NCBI chrNW_004936631:484,356...489,643
Ensembl chrNW_004936631:484,356...489,643
|
|
G |
Ctnnb1 |
catenin beta 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism associated with Prostatic Neoplasms |
CTD RGD |
PMID:18008331 PMID:29106415 |
RGD:2289488 |
NCBI chrNW_004936473:29,999,542...30,034,610
Ensembl chrNW_004936473:29,999,562...30,038,293
|
|
G |
Ctsd |
cathepsin D |
|
ISO |
protein:increased expression:oral cavity, oropharynx, hypopharynx (human) |
RGD |
PMID:10562684 |
RGD:1547892 |
NCBI chrNW_004936816:680,798...690,959
Ensembl chrNW_004936816:680,798...691,039
|
|
G |
Ctsh |
cathepsin H |
|
ISO |
protein:increased expression:cerebrospinal fluid |
RGD |
PMID:12589965 |
RGD:5686394 |
NCBI chrNW_004936471:37,135,200...37,156,081
Ensembl chrNW_004936471:37,131,817...37,156,476
|
|
G |
Ctu1 |
cytosolic thiouridylase subunit 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27811057 |
|
NCBI chrNW_004936889:728,956...735,692
Ensembl chrNW_004936889:728,362...733,141
|
|
G |
Ctu2 |
cytosolic thiouridylase subunit 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27811057 |
|
NCBI chrNW_004936641:980,493...986,015
Ensembl chrNW_004936641:980,533...984,506
|
|
G |
Cx3cr1 |
C-X3-C motif chemokine receptor 1 |
susceptibility |
ISO |
associated with Breast Neoplasms |
RGD |
PMID:16627550 |
RGD:4892015 |
NCBI chrNW_004936473:28,508,726...28,535,640
Ensembl chrNW_004936473:28,510,523...28,535,627
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
treatment |
ISO |
associated with Pancreatic Carcinoma associated with Pancreatic Neoplasms CTD Direct Evidence: marker/mechanism |
RGD CTD |
PMID:12761880 PMID:21312072 PMID:23743303 PMID:26330165 |
RGD:10398726 RGD:2317610 |
NCBI chrNW_004936617:4,224,131...4,239,080
Ensembl chrNW_004936617:4,224,131...4,238,796
|
|
G |
Cxcr3 |
C-X-C motif chemokine receptor 3 |
|
ISO |
associated with Mammary Neoplasms, Experimental |
RGD |
PMID:16885372 |
RGD:5135487 |
NCBI chrNW_004936762:66,636...69,694
Ensembl chrNW_004936762:66,636...69,373
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
ameliorates severity disease_progression |
ISO |
CTD Direct Evidence: marker/mechanism associated with oral squamous cell carcinoma associated with Otorhinolaryngologic Neoplasms;mRNA,protein:increased expression:Laryngeal and hypopharyngeal tissue (human) associated with lung non-small cell carcinoma;mRNA,protein:increased expression:lung (human) associated with lung non-small cell carcinoma; protein:increased expression:lung (human) associated with pancreatic cancer associated with osteosarcoma;protein:increased expression:bone (human) human cells in mouse model;associated with lung cancer associated with lung cancer; human cells in mouse model |
CTD RGD |
PMID:16230077 PMID:16322285 PMID:17634424 PMID:18487224 PMID:21312072 PMID:23743303 PMID:24932250 PMID:25504108 PMID:26546437 PMID:28000861 PMID:32037613 More...
|
RGD:151708730 RGD:152023741 RGD:152023745 RGD:152023746 RGD:152025556 RGD:152177475 RGD:152177476 RGD:152177478 RGD:152177479 |
NCBI chrNW_004936469:39,794,613...39,798,448
Ensembl chrNW_004936469:39,794,584...39,798,459
|
|
G |
Dab2ip |
DAB2 interacting protein |
severity |
ISO |
associated with colorectal cancer;protein:decreased expression:colorectum (human) |
RGD |
PMID:26336990 |
RGD:11531913 |
NCBI chrNW_004936487:10,056,809...10,243,021
Ensembl chrNW_004936487:10,145,278...10,243,174
|
|
G |
Dapk1 |
death associated protein kinase 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:17319784 |
|
NCBI chrNW_004936680:2,842,930...3,020,757
Ensembl chrNW_004936680:2,842,547...3,021,058
|
|
G |
Daxx |
death domain associated protein |
|
ISO |
|
RGD |
PMID:23539629 |
RGD:9587820 |
NCBI chrNW_004936476:25,546,091...25,550,390
Ensembl chrNW_004936476:25,546,036...25,550,392
|
|
G |
Dcn |
decorin |
|
ISO |
associated with Breast Neoplasms |
RGD |
PMID:18688028 |
RGD:2311418 |
NCBI chrNW_004936507:7,887,259...7,923,055
Ensembl chrNW_004936507:7,884,654...7,922,961
|
|
G |
Ddr1 |
discoidin domain receptor tyrosine kinase 1 |
severity |
ISO |
protein:increased expression:bone (human) mRNA:increased expression:ovary (human) |
RGD |
PMID:28743276 PMID:29039472 |
RGD:151347541 RGD:151347601 |
NCBI chrNW_004936837:523,227...538,799
Ensembl chrNW_004936837:523,266...538,833
|
|
G |
Ddr2 |
discoidin domain receptor tyrosine kinase 2 |
ameliorates |
ISO |
associated with melanoma; |
RGD |
PMID:24293323 |
RGD:150429711 |
NCBI chrNW_004936831:799,948...946,139
Ensembl chrNW_004936831:865,965...946,139
|
|
G |
Ddx3x |
DEAD-box helicase 3 X-linked |
|
ISO |
human cells in mouse model |
RGD |
PMID:26087195 |
RGD:11096798 |
NCBI chrNW_004936502:7,770,896...7,820,555
Ensembl chrNW_004936502:7,804,824...7,820,569
|
|
G |
Dek |
DEK proto-oncogene |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27811057 |
|
NCBI chrNW_004936552:3,964,515...3,997,318
Ensembl chrNW_004936552:3,966,198...3,993,113
|
|
G |
Dhfr |
dihydrofolate reductase |
disease_progression |
ISO |
CTD Direct Evidence: marker/mechanism |
CTD RGD |
PMID:8149482 PMID:19159907 |
RGD:11040442 |
NCBI chrNW_004936469:67,962...83,116
|
|
G |
Dio3 |
iodothyronine deiodinase 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26825960 |
|
NCBI chrNW_004936604:5,241,877...5,243,910
|
|
G |
Dmd |
dystrophin |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:24793134 |
|
NCBI chrNW_004936553:7,157,526...7,943,703
|
|
G |
Dnmt3b |
DNA methyltransferase 3 beta |
|
ISO |
associated with Uterine Cervical Neoplasms; |
RGD |
PMID:22330137 |
RGD:9589117 |
NCBI chrNW_004936485:19,547,836...19,570,716
|
|
G |
Dpyd |
dihydropyrimidine dehydrogenase |
treatment |
ISO |
associated with Colonic Neoplasms CTD Direct Evidence: marker/mechanism |
RGD CTD |
PMID:11383214 PMID:17611699 |
RGD:11251755 |
NCBI chrNW_004936537:1,660,461...2,439,305
Ensembl chrNW_004936537:1,660,477...2,439,273
|
|
G |
E2f1 |
E2F transcription factor 1 |
severity |
ISO |
protein:increased expression:bone (human) |
RGD |
PMID:29039472 |
RGD:151347601 |
NCBI chrNW_004936561:6,894,827...6,901,058
Ensembl chrNW_004936561:6,896,063...6,900,026
|
|
G |
E2f8 |
E2F transcription factor 8 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27683099 |
|
NCBI chrNW_004936654:322,863...339,365
Ensembl chrNW_004936654:322,863...338,699
|
|
G |
Edn1 |
endothelin 1 |
|
ISO |
|
RGD |
PMID:12941866 |
RGD:734914 |
NCBI chrNW_004936534:885,489...892,292
Ensembl chrNW_004936534:885,287...891,772
|
|
G |
Ednra |
endothelin receptor type A |
|
ISO |
associated with Bladder Neoplasms |
RGD |
PMID:21183790 |
RGD:4892282 |
NCBI chrNW_004936535:1,950,117...2,005,786
Ensembl chrNW_004936535:1,949,941...2,005,910
|
|
G |
Eef1b2 |
eukaryotic translation elongation factor 1 beta 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:17085005 PMID:20562527 |
|
NCBI chrNW_004936631:2,539,075...2,542,252
Ensembl chrNW_004936631:2,539,070...2,542,419
|
|
G |
Eef2 |
eukaryotic translation elongation factor 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20562527 |
|
NCBI chrNW_004936588:2,259,236...2,267,692
Ensembl chrNW_004936588:2,258,309...2,266,609
|
|
G |
Efnb2 |
ephrin B2 |
|
ISO |
associated with cholangiocarcinoma;protein:increased expression:biliary ductule (human) |
RGD |
PMID:25012246 |
RGD:153305948 |
NCBI chrNW_004936472:5,138,751...5,181,630
Ensembl chrNW_004936472:5,138,745...5,181,668
|
|
G |
Egf |
epidermal growth factor |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21942447 PMID:23064031 |
|
NCBI chrNW_004936563:1,058,803...1,181,393
|
|
G |
Egfr |
epidermal growth factor receptor |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:17369752 PMID:17575224 PMID:23867902 |
|
NCBI chrNW_004936678:365,005...560,546
Ensembl chrNW_004936678:365,834...436,528
|
|
G |
Ehmt2 |
euchromatic histone lysine methyltransferase 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism associated with lung neoplasms; |
CTD RGD |
PMID:20940408 PMID:25115793 |
RGD:9589170 |
NCBI chrNW_004936727:1,648,451...1,663,294
Ensembl chrNW_004936727:1,648,448...1,663,455
|
|
G |
Eif1ax |
eukaryotic translation initiation factor 1A X-linked |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:17085005 |
|
NCBI chrNW_004936624:4,010,912...4,029,520
Ensembl chrNW_004936624:4,010,753...4,030,374
|
|
G |
Eif4a2 |
eukaryotic translation initiation factor 4A2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:17085005 |
|
NCBI chrNW_004936578:3,219,842...3,225,261
|
|
G |
Elp3 |
elongator acetyltransferase complex subunit 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27811057 |
|
NCBI chrNW_004936675:933,698...1,014,919
Ensembl chrNW_004936675:933,676...1,016,242
|
|
G |
Eml4 |
EMAP like 4 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22986231 PMID:22999080 |
|
NCBI chrNW_004936508:9,303,639...9,447,478
Ensembl chrNW_004936508:9,303,639...9,447,548
|
|
G |
Enpp2 |
ectonucleotide pyrophosphatase/phosphodiesterase 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26037280 |
|
NCBI chrNW_004936470:26,994,549...27,099,758
Ensembl chrNW_004936470:26,994,215...27,100,999
|
|
G |
Epcam |
epithelial cell adhesion molecule |
|
ISO |
|
RGD |
PMID:23390083 |
RGD:9685143 |
NCBI chrNW_004936508:5,019,513...5,032,610
Ensembl chrNW_004936508:5,019,918...5,032,414
|
|
G |
Epo |
erythropoietin |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:16699298 |
|
NCBI chrNW_004936543:742,722...745,332
Ensembl chrNW_004936543:743,537...745,343
|
|
G |
Epor |
erythropoietin receptor |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:16699298 |
|
NCBI chrNW_004936659:1,468,391...1,473,880
Ensembl chrNW_004936659:1,468,634...1,473,880
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
|
ISO |
rat gene in a mouse model CTD Direct Evidence: marker/mechanism |
RGD CTD |
PMID:11238891 PMID:16984552 |
RGD:734938 |
NCBI chrNW_004936490:14,887,062...14,910,038
Ensembl chrNW_004936490:14,887,043...14,909,956
|
|
G |
Erbb3 |
erb-b2 receptor tyrosine kinase 3 |
disease_progression |
ISO |
associated with Prostatic Neoplasms;protein:alternative form associated with lung adenocarcinoma associated with Prostatic Neoplasms;protein:increased expression, altered localization:bone, nucleus CTD Direct Evidence: marker/mechanism |
RGD CTD |
PMID:17634423 PMID:18559590 PMID:26254096 PMID:28114269 |
RGD:126790470 RGD:2289944 RGD:2298500 |
NCBI chrNW_004936646:497,783...515,247
Ensembl chrNW_004936646:498,749...513,297
|
|
G |
Erbb4 |
erb-b2 receptor tyrosine kinase 4 |
disease_progression |
ISO |
associated with lung adenocarcinoma |
RGD |
PMID:26254096 |
RGD:126790470 |
NCBI chrNW_004936586:4,065,767...5,100,690
Ensembl chrNW_004936586:4,066,498...5,100,035
|
|
G |
Ercc1 |
ERCC excision repair 1, endonuclease non-catalytic subunit |
disease_progression |
ISO |
associated with Melanoma CTD Direct Evidence: marker/mechanism |
RGD CTD |
PMID:20801905 PMID:26202595 |
RGD:11252177 |
NCBI chrNW_004936706:1,854,938...1,867,521
Ensembl chrNW_004936706:1,852,359...1,867,745
|
|
G |
Ercc4 |
ERCC excision repair 4, endonuclease catalytic subunit |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20372803 |
|
NCBI chrNW_004936501:2,301,072...2,329,346
Ensembl chrNW_004936501:2,300,835...2,329,351
|
|
G |
Erp29 |
endoplasmic reticulum protein 29 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:17085005 |
|
NCBI chrNW_004936558:4,531,397...4,538,943
Ensembl chrNW_004936558:4,531,471...4,538,943
|
|
G |
Esr1 |
estrogen receptor 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20104649 PMID:35044086 |
|
NCBI chrNW_004936489:4,616,839...4,887,179
Ensembl chrNW_004936489:4,614,754...4,887,171
|
|
G |
Etv4 |
ETS variant transcription factor 4 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27869830 |
|
NCBI chrNW_004936541:120,533...138,463
Ensembl chrNW_004936541:123,049...139,256
|
|
G |
Ezh2 |
enhancer of zeste 2 polycomb repressive complex 2 subunit |
|
ISO |
associated with osteosarcoma associated with stomach cancer;protein:increased expression:stomach associated with lung non-small cell carcinoma |
RGD |
PMID:20132185 PMID:24097870 PMID:26265454 |
RGD:11532507 RGD:126779607 RGD:126781716 |
NCBI chrNW_004936527:5,024,077...5,069,152
Ensembl chrNW_004936527:5,024,068...5,063,939
|
|
G |
Ezr |
ezrin |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27137931 |
|
NCBI chrNW_004936489:10,413,374...10,457,771
Ensembl chrNW_004936489:10,412,710...10,458,201
|
|
G |
F2 |
coagulation factor II, thrombin |
|
ISO |
associated with Carcinoma, Small cell;protein:increased expression:brain |
RGD |
PMID:22065054 |
RGD:6893520 |
NCBI chrNW_004936562:2,371,725...2,388,617
Ensembl chrNW_004936562:2,372,044...2,388,650
|
|
G |
Fadd |
Fas associated via death domain |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:16450001 |
|
NCBI chrNW_004936599:633,501...639,412
Ensembl chrNW_004936599:633,330...639,456
|
|
G |
Fas |
Fas cell surface death receptor |
|
ISO |
associated with Mammary Neoplasms;protein:decreased expression:lung associated with Breast Neoplasms;protein:decreased expression:breast |
RGD |
PMID:17352235 PMID:17918178 |
RGD:2290048 RGD:2290053 |
NCBI chrNW_004936735:209,369...234,582
|
|
G |
Faslg |
Fas ligand |
|
ISO |
associated with Breast Neoplasms;protein:decreased expression:breast |
RGD |
PMID:17352235 |
RGD:2290053 |
NCBI chrNW_004936481:14,789,547...14,795,780
|
|
G |
Fgf13 |
fibroblast growth factor 13 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19917848 |
|
NCBI chrNW_004936513:8,419,588...8,911,010
Ensembl chrNW_004936513:8,714,396...8,911,367
|
|
G |
Fgfr1 |
fibroblast growth factor receptor 1 |
|
ISO |
associated with prostate adenocarcinoma |
RGD |
PMID:23576558 |
RGD:13504748 |
NCBI chrNW_004936710:1,760,365...1,815,269
Ensembl chrNW_004936710:1,760,089...1,815,508
|
|
G |
Flt1 |
fms related receptor tyrosine kinase 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21975929 |
|
NCBI chrNW_004936472:23,442,946...23,617,523
Ensembl chrNW_004936472:23,440,088...23,617,041
|
|
G |
Fn1 |
fibronectin 1 |
treatment |
ISO |
associated with stomach cancer; human cells in mouse model |
RGD |
PMID:27431311 |
RGD:152995400 |
NCBI chrNW_004936586:1,708,803...1,773,372
Ensembl chrNW_004936586:1,708,684...1,773,383
|
|
G |
Fscn1 |
fascin actin-bundling protein 1 |
|
ISO |
associated with Pancreatic Neoplasms |
RGD |
PMID:15626919 |
RGD:2317788 |
NCBI chrNW_004936765:609,894...619,417
Ensembl chrNW_004936765:609,861...619,456
|
|
G |
Ftl |
ferritin light chain |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:17085005 |
|
NCBI chrNW_004936664:2,976,325...2,977,878
Ensembl chrNW_004936664:2,976,314...2,977,877
|
|
G |
Gab2 |
GRB2 associated binding protein 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21996746 |
|
NCBI chrNW_004936498:6,775,170...6,835,680
Ensembl chrNW_004936498:6,778,462...6,835,643
|
|
G |
Gdf15 |
growth differentiation factor 15 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:23996089 |
|
NCBI chrNW_004936596:2,854,620...2,857,018
Ensembl chrNW_004936596:2,854,841...2,857,111
|
|
G |
Gjb1 |
gap junction protein beta 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:17978847 |
|
NCBI chrNW_004936762:389,655...398,035
Ensembl chrNW_004936762:389,669...395,898
|
|
G |
Gp1ba |
glycoprotein Ib platelet subunit alpha |
|
ISO |
associated with Melanoma, Experimental |
RGD |
PMID:19727118 |
RGD:10450866 |
NCBI chrNW_004936677:2,774,076...2,779,660
|
|
G |
Gpcpd1 |
glycerophosphocholine phosphodiesterase 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:25482527 |
|
NCBI chrNW_004936485:13,401,598...13,458,125
Ensembl chrNW_004936485:13,400,995...13,458,146
|
|
G |
Gpi |
glucose-6-phosphate isomerase |
|
ISO |
|
RGD |
PMID:20978190 |
RGD:11051956 |
NCBI chrNW_004936570:1,582,120...1,608,537
Ensembl chrNW_004936570:1,579,372...1,608,788
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:23867582 |
|
NCBI chrNW_004936495:8,590,225...8,593,511
Ensembl chrNW_004936495:8,590,556...8,593,367
|
|
G |
Habp2 |
hyaluronan binding protein 2 |
treatment |
ISO |
associated with Thyroid Neoplasms |
RGD |
PMID:22715430 |
RGD:11353856 |
NCBI chrNW_004936486:3,987,746...4,004,632
Ensembl chrNW_004936486:3,974,035...4,004,632
|
|
G |
Havcr2 |
hepatitis A virus cellular receptor 2 |
disease_progression |
ISO |
DNA:polymorphisms: : +4259T>G (human) |
RGD |
PMID:22472081 |
RGD:7245505 |
NCBI chrNW_004936515:6,001,324...6,015,407
|
|
G |
Hdac3 |
histone deacetylase 3 |
|
ISO |
associated with Anaphylaxis; CTD Direct Evidence: marker/mechanism |
RGD CTD |
PMID:24619412 PMID:34973135 |
RGD:9590165 |
NCBI chrNW_004936504:12,530,546...12,546,556
Ensembl chrNW_004936504:12,530,528...12,546,556
|
|
G |
Hgf |
hepatocyte growth factor |
|
ISO |
CTD Direct Evidence: marker/mechanism associated with Melanoma; associated with Mammary Neoplasms, Experimental; associated with Pancreatic Neoplasms |
CTD RGD |
PMID:10688652 PMID:11893931 PMID:16459153 PMID:25971889 |
RGD:2317904 RGD:8548538 RGD:8548625 |
NCBI chrNW_004936734:354,798...428,356
Ensembl chrNW_004936734:356,115...428,779
|
|
G |
Hpse |
heparanase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22240343 |
|
NCBI chrNW_004936738:1,308,350...1,341,421
Ensembl chrNW_004936738:1,308,345...1,343,145
|
|
G |
Hrh2 |
histamine receptor H2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:6224980 |
|
NCBI chrNW_004936609:624,446...664,049
Ensembl chrNW_004936609:622,311...664,084
|
|
G |
Hsp90aa1 |
heat shock protein 90 alpha family class A member 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:20562527 |
|
NCBI chrNW_004936835:316,767...321,999
Ensembl chrNW_004936835:316,767...321,990
|
|
G |
Ibsp |
integrin binding sialoprotein |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22407340 PMID:24980816 |
|
NCBI chrNW_004936905:316,459...323,446
Ensembl chrNW_004936905:316,459...323,446
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
|
ISO |
associated with Melanoma, Cutaneous Malignant associated with Pancreatic Neoplasms;protein:increased expression:serum |
RGD |
PMID:10465581 PMID:12923961 |
RGD:2325163 RGD:8547593 |
NCBI chrNW_004936659:616,570...627,172
Ensembl chrNW_004936659:616,752...627,174
|
|
G |
Id1 |
inhibitor of DNA binding 1, HLH protein |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:24910342 |
|
NCBI chrNW_004936485:18,610,721...18,611,889
Ensembl chrNW_004936485:18,610,665...18,612,059
|
|
G |
Igf1 |
insulin like growth factor 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism associated with Pancreatic Neoplasms associated with Uveal Melanoma;protein:increased expression:serum: |
CTD RGD |
PMID:18398872 PMID:19375852 PMID:23197685 |
RGD:2317643 RGD:8548834 |
NCBI chrNW_004936492:11,709,623...11,784,028
Ensembl chrNW_004936492:11,709,222...11,778,351
|
|
G |
Igf1r |
insulin like growth factor 1 receptor |
|
ISO |
associated with Pancreatic Neoplasms |
RGD |
PMID:16575403 |
RGD:2317645 |
NCBI chrNW_004936483:4,563,995...4,860,231
Ensembl chrNW_004936483:4,564,512...4,852,925
|
|
G |
Igf2 |
insulin like growth factor 2 |
|
ISO |
associated with Arthritis, Experimental; protein:increased expression:lung, bone, serum: |
RGD |
PMID:21859454 |
RGD:5510000 |
NCBI chrNW_004936816:972,902...981,232
Ensembl chrNW_004936816:972,282...979,167
|
|
G |
Ikzf1 |
IKAROS family zinc finger 1 |
|
ISO |
associated with colorectal cancer;DNA:polymorphisms: |
RGD |
PMID:31320627 |
RGD:150540328 |
NCBI chrNW_004936686:1,459,582...1,556,478
Ensembl chrNW_004936686:1,462,145...1,556,451
|
|
G |
Il10 |
interleukin 10 |
|
ISO |
|
RGD |
PMID:16035616 |
RGD:1598627 |
NCBI chrNW_004936557:5,834,874...5,838,502
Ensembl chrNW_004936557:5,834,874...5,838,502
|
|
G |
Il18 |
interleukin 18 |
|
ISO |
associated with breast cancer;DNA:SNP:promoter:-137G>C (rs187238) (human) associated with breast cancer;protein:increased expression:serum CTD Direct Evidence: marker/mechanism |
RGD CTD |
PMID:11215816 PMID:12209760 PMID:12748951 PMID:19152241 |
RGD:4889862 RGD:8655866 RGD:8655899 |
NCBI chrNW_004936612:2,306,963...2,325,086
Ensembl chrNW_004936612:2,306,875...2,325,189
|
|
G |
Il2 |
interleukin 2 |
treatment |
ISO |
associated with melanoma; associated with neuroblastoma. CTD Direct Evidence: therapeutic |
RGD CTD |
PMID:8610104 PMID:8642346 PMID:9362156 PMID:17105418 |
RGD:14747043 RGD:14865005 RGD:8663438 |
NCBI chrNW_004936662:1,594,953...1,599,625
Ensembl chrNW_004936662:1,594,953...1,599,625
|
|
G |
Il6 |
interleukin 6 |
treatment |
ISO |
associated with stomach cancer, human cells in mouse model CTD Direct Evidence: marker/mechanism |
RGD CTD |
PMID:21937440 PMID:26101800 PMID:28186964 |
RGD:127229952 |
NCBI chrNW_004936549:7,015,595...7,016,246
|
|
G |
Itga6 |
integrin subunit alpha 6 |
|
ISO |
|
RGD |
PMID:13130099 |
RGD:1302259 |
NCBI chrNW_004936509:2,508,446...2,587,643
Ensembl chrNW_004936509:2,508,375...2,587,669
|
|
G |
Itgb1 |
integrin subunit beta 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:23562787 |
|
NCBI chrNW_004936574:1,465,981...1,495,717
Ensembl chrNW_004936574:1,465,897...1,495,762
|
|
G |
Itgb3 |
integrin subunit beta 3 |
|
ISO |
associated with renal cell carcinoma;DNA:missense mutation:cds:p.L33P (human) mRNA, protein:increased expression:lung |
RGD |
PMID:16831169 PMID:21107114 |
RGD:5037225 RGD:6907406 |
NCBI chrNW_004936541:2,822,789...2,871,069
Ensembl chrNW_004936541:2,815,738...2,871,035
|
|
G |
Jak2 |
Janus kinase 2 |
treatment |
ISO |
associated with stomach cancer, human cells in mouse model |
RGD |
PMID:28186964 |
RGD:127229952 |
NCBI chrNW_004936503:111,722...243,627
Ensembl chrNW_004936503:110,963...241,867
|
|
G |
Jup |
junction plakoglobin |
|
ISO |
associated with Ovarian Neoplasms |
RGD |
PMID:15619205 |
RGD:2301746 |
NCBI chrNW_004936490:16,671,176...16,694,552
Ensembl chrNW_004936490:16,668,575...16,694,615
|
|
G |
Kdm6a |
lysine demethylase 6A |
disease_progression |
ISO |
associated with lung adenocarcinoma;protein:increased expression:brain (human) |
RGD |
PMID:33291558 |
RGD:150429741 |
NCBI chrNW_004936502:10,980,303...11,196,711
Ensembl chrNW_004936502:10,980,118...11,196,163
|
|
G |
Kdr |
kinase insert domain receptor |
|
ISO |
associated with Carcinoma, Renal Cell |
RGD |
PMID:17465216 |
RGD:2301757 |
NCBI chrNW_004936482:17,537,697...17,581,320
Ensembl chrNW_004936482:17,538,864...17,581,002
|
|
G |
Kif2c |
kinesin family member 2C |
disease_progression |
ISO |
associated with colorectal cancer |
RGD |
PMID:18506187 |
RGD:27372891 |
NCBI chrNW_004936474:25,967,095...26,000,678
Ensembl chrNW_004936474:25,978,707...26,000,140
|
|
G |
Kiss1 |
KiSS-1 metastasis suppressor |
|
ISO |
associated with Ovarian Neoplasms |
RGD |
PMID:16283480 |
RGD:2298668 |
NCBI chrNW_004936567:584,443...595,045
Ensembl chrNW_004936567:584,443...586,837
|
|
G |
Kmt2b |
lysine methyltransferase 2B |
|
ISO |
associated with lung adenocarcinoma |
RGD |
PMID:33291558 |
RGD:150429741 |
NCBI chrNW_004936570:583,616...605,846
Ensembl chrNW_004936570:583,616...605,603
|
|
G |
Kmt2d |
lysine methyltransferase 2D |
disease_progression |
ISO |
associated with colorectal cancer;DNA:mutations:: |
RGD |
PMID:27875625 |
RGD:155582219 |
NCBI chrNW_004936512:6,819,240...6,860,852
Ensembl chrNW_004936512:6,822,057...6,854,451
|
|
G |
Kras |
KRAS proto-oncogene, GTPase |
treatment disease_progression |
ISO |
associated with colorectal cancer; DNA:mutation:cds: associated with stomach cancer; human cells in mouse model associated with colorectal cancer;DNA:mutation: : associated with Fibrosarcoma;mRNA,protein:decreased expression:: CTD Direct Evidence: marker/mechanism associated with colorectal cancer;DNA:mutations: : |
RGD CTD |
PMID:3552201 PMID:8635384 PMID:26210240 PMID:27264476 PMID:27431311 PMID:29032374 More...
|
RGD:11086960 RGD:11570402 RGD:14398745 RGD:14398751 RGD:152995400 |
NCBI chrNW_004936548:2,078,568...2,113,877
Ensembl chrNW_004936548:2,079,036...2,110,523
|
|
G |
Krt20 |
keratin 20 |
|
ISO |
associated with Colorectal Neoplasms |
RGD |
PMID:10931219 |
RGD:2317676 |
|
|
G |
L1cam |
L1 cell adhesion molecule |
treatment |
ISO |
associated with Lung Neoplasms; associated with Pancreatic Neoplasms; |
RGD |
PMID:22095073 PMID:22307136 |
RGD:11570404 RGD:11570503 |
NCBI chrNW_004936809:736,385...768,822
Ensembl chrNW_004936809:736,319...761,973
|
|
G |
Lamc2 |
laminin subunit gamma 2 |
|
ISO |
associated with lung adenocarcinoma; |
RGD |
PMID:25591736 |
RGD:11075980 |
NCBI chrNW_004936481:6,588,797...6,647,167
Ensembl chrNW_004936481:6,588,865...6,647,188
|
|
G |
Lcn2 |
lipocalin 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:24570342 |
|
NCBI chrNW_004936487:15,721,752...15,725,396
Ensembl chrNW_004936487:15,721,684...15,728,221
|
|
G |
Lect2 |
leukocyte cell derived chemotaxin 2 |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:30453282 |
|
NCBI chrNW_004936597:3,051,143...3,057,383
Ensembl chrNW_004936597:3,051,143...3,057,383
|
|
G |
Lef1 |
lymphoid enhancer binding factor 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism associated with prostate cancer |
CTD RGD |
PMID:27067790 PMID:27811057 |
RGD:11531513 |
NCBI chrNW_004936818:453,635...569,194
Ensembl chrNW_004936818:453,635...567,469
|
|
G |
Lgals3 |
galectin 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:25882088 |
|
NCBI chrNW_004936697:20,861...38,568
Ensembl chrNW_004936697:27,145...38,586
|
|
G |
Llgl2 |
LLGL scribble cell polarity complex component 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28114269 |
|
NCBI chrNW_004936594:754,140...792,493
Ensembl chrNW_004936594:765,310...792,155
|
|
G |
LOC101954950 |
aromatase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28112739 |
|
NCBI chrNW_004936471:13,107,603...13,136,910
Ensembl chrNW_004936471:13,107,603...13,136,910
|
|
G |
LOC101956126 |
heat shock 70 kDa protein 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:26984758 |
|
NCBI chrNW_004936727:1,732,323...1,735,128
|
|
G |
LOC101964702 |
adhesion G protein-coupled receptor B1 |
|
ISO |
associated with colorectal cancer |
RGD |
PMID:9772287 |
RGD:13831353 |
NCBI chrNW_004936470:9,247,749...9,313,230
Ensembl chrNW_004936470:9,248,319...9,313,230
|
|
G |
LOC101968921 |
angiotensin-converting enzyme |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:18059164 |
|
NCBI chrNW_004936541:4,157,847...4,178,156
Ensembl chrNW_004936541:4,157,393...4,178,177
|
|
G |
LOC101976513 |
calmodulin-like protein 3 |
ameliorates |
ISO |
associated with hepatocellular carcinoma; human cells in mouse model associated with hepatocellular carcinoma; protein:decreased expression:liver (human) |
RGD |
PMID:29445139 |
RGD:151665319 |
NCBI chrNW_004936484:8,976,512...8,977,792
Ensembl chrNW_004936484:8,977,252...8,977,701
|
|
G |
Ly96 |
lymphocyte antigen 96 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22180778 |
|
NCBI chrNW_004936648:2,653,252...2,671,453
|
|
G |
Macc1 |
MET transcriptional regulator MACC1 |
treatment |
ISO |
associated with stomach cancer; human cells in mouse model CTD Direct Evidence: marker/mechanism |
RGD CTD |
PMID:27431311 PMID:36008464 |
RGD:152995400 |
NCBI chrNW_004936546:6,169,789...6,188,403
Ensembl chrNW_004936546:6,167,616...6,232,771
|
|
G |
Map2k4 |
mitogen-activated protein kinase kinase 4 |
disease_progression |
ISO |
associated with oral squamous cell carcinoma;mRNA, protein:increased expression:lymph node (human) |
RGD |
PMID:22165133 |
RGD:150429749 |
NCBI chrNW_004936595:4,762,327...4,828,433
Ensembl chrNW_004936595:4,727,108...4,830,662
|
|
G |
Mapk1 |
mitogen-activated protein kinase 1 |
treatment |
ISO |
associated with prostate adenocarcinoma CTD Direct Evidence: marker/mechanism |
RGD CTD |
PMID:22139534 PMID:22580338 |
RGD:13504820 |
NCBI chrNW_004936619:1,889,841...1,932,646
Ensembl chrNW_004936619:1,889,708...1,932,646
|
|
G |
Mapk3 |
mitogen-activated protein kinase 3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22580338 |
|
NCBI chrNW_004936501:12,342,670...12,390,650
Ensembl chrNW_004936501:12,384,804...12,392,180
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
|
ISO |
CTD Direct Evidence: therapeutic associated with Colorectal Neoplasms |
CTD RGD |
PMID:21779479 PMID:25205654 |
RGD:13217416 |
NCBI chrNW_004936739:551,678...602,027
Ensembl chrNW_004936739:551,629...602,047
|
|
G |
Med28 |
mediator complex subunit 28 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21942447 |
|
NCBI chrNW_004936477:10,586,436...10,592,366
|
|
G |
Met |
MET proto-oncogene, receptor tyrosine kinase |
disease_progression |
ISO |
associated with Squamous Cell Carcinoma of the Tongue; CTD Direct Evidence: marker/mechanism |
RGD CTD |
PMID:20080979 PMID:21225626 PMID:22704061 |
RGD:8548616 |
NCBI chrNW_004936589:2,280,803...2,390,179
Ensembl chrNW_004936589:2,280,799...2,390,179
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
|
ISO |
associated with Pancreatic Neoplasms |
RGD |
PMID:20388395 |
RGD:2317702 |
NCBI chrNW_004936486:15,561,327...15,587,109
|
|
G |
Mlh1 |
mutL homolog 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:17717427 |
|
NCBI chrNW_004936473:26,556,636...26,600,830
Ensembl chrNW_004936473:26,556,611...26,603,736
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:12538496 PMID:19487542 PMID:22580338 PMID:23548910 |
|
NCBI chrNW_004936551:5,167,909...5,175,149
Ensembl chrNW_004936551:5,168,044...5,174,857
|
|
G |
Mmp10 |
matrix metallopeptidase 10 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22022614 |
|
NCBI chrNW_004936551:5,188,395...5,197,477
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
|
ISO |
associated with Carcinoma, Renal Cell;mRNA, protein:increased expression:bone |
RGD |
PMID:18709334 |
RGD:2306080 |
NCBI chrNW_004936551:5,040,084...5,050,384
Ensembl chrNW_004936551:5,040,084...5,050,384
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
disease_progression |
ISO |
associated with Mammary Neoplasms, Animal;protein:increased expression:brain CTD Direct Evidence: marker/mechanism associated with Gallbladder Neoplasms; protein:increased expression:gallbladder associated with pancreatic cancer; protein:increased expression, increased activity:pancreas |
RGD CTD |
PMID:12173379 PMID:16158251 PMID:16475674 PMID:18398872 PMID:18665467 PMID:21209944 PMID:22321834 PMID:23707804 PMID:30603057 More...
|
RGD:2325743 RGD:2325749 RGD:8547884 |
NCBI chrNW_004936475:7,801,356...7,825,831
Ensembl chrNW_004936475:7,801,277...7,825,851
|
|
G |
Mmp24 |
matrix metallopeptidase 24 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27869830 |
|
NCBI chrNW_004936561:5,479,107...5,501,559
Ensembl chrNW_004936561:5,478,145...5,502,529
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
severity disease_progression |
ISO |
CTD Direct Evidence: marker/mechanism associated with osteosarcoma;protein:increased expression:bone (human) associated with pancreatic cancer; protein:increased expression, increased activity:pancreas associated with skin melanoma;DNA:missense mutation:cds:p.Q279R (human) associated with Mammary Neoplasms, Animal associated with Mammary Neoplasms, Animal; associated with Arthritis, Experimental associated with Mammary Neoplasms, Animal;protein:increased expression:brain associated with carcinoma, pancreatic ductal; protein:increased expression:pancreas associated with Melanoma |
RGD CTD |
PMID:8912869 PMID:12173379 PMID:15659795 PMID:16033831 PMID:16158251 PMID:16475674 PMID:17346338 PMID:17378244 PMID:18676849 PMID:18930813 PMID:21209944 PMID:21859454 PMID:21942447 PMID:26546437 PMID:34626302 More...
|
RGD:152023746 RGD:2325749 RGD:2325855 RGD:5510000 RGD:8547861 RGD:8547878 RGD:8547884 RGD:8547886 RGD:8547928 |
NCBI chrNW_004936514:7,038,240...7,045,873
Ensembl chrNW_004936514:7,037,639...7,045,793
|
|
G |
Msh2 |
mutS homolog 2 |
|
ISO |
associated with Breast Neoplasms |
RGD |
PMID:17390069 |
RGD:2293506 |
NCBI chrNW_004936508:4,943,987...5,013,356
Ensembl chrNW_004936508:4,944,007...5,013,356
|
|
G |
Mst1 |
macrophage stimulating 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28114269 |
|
NCBI chrNW_004936529:1,298,853...1,306,088
Ensembl chrNW_004936529:1,299,300...1,303,959
|
|
G |
Mtdh |
metadherin |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:19111877 |
|
NCBI chrNW_004936470:45,016,099...45,079,709
Ensembl chrNW_004936470:45,016,099...45,079,710
|
|
G |
Mthfr |
methylenetetrahydrofolate reductase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:17704422 |
|
NCBI chrNW_004936474:623,438...637,849
Ensembl chrNW_004936474:623,291...638,193
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
|
ISO |
associated with Pancreatic Neoplasms |
RGD |
PMID:23149918 |
RGD:10040959 |
NCBI chrNW_004936474:158,376...282,310
Ensembl chrNW_004936474:157,590...282,342
|
|
G |
Muc1 |
mucin 1, cell surface associated |
disease_progression |
ISO |
associated with Carcinoma, Renal Cell; associated with Pancreatic Neoplasms |
RGD |
PMID:10390012 PMID:12941828 PMID:16707592 |
RGD:2324648 RGD:2324652 RGD:7245968 |
NCBI chrNW_004936580:4,691,870...4,694,092
|
|
G |
Muc4 |
mucin 4, cell surface associated |
|
ISO |
associated with Melanoma |
RGD |
PMID:10918186 |
RGD:2303746 |
NCBI chrNW_004936784:515,608...539,915
|
|
G |
Muc5ac |
mucin 5AC, oligomeric mucus/gel-forming |
|
ISO |
associated with chloangiocarcinoma;protein:increased expression:bile duct |
RGD |
PMID:16124042 |
RGD:2324987 |
NCBI chrNW_004936816:129,926...159,396
|
|
G |
Muc6 |
mucin 6, oligomeric mucus/gel-forming |
disease_progression |
ISO |
associated with cholangiocarcinoma |
RGD |
PMID:18410610 |
RGD:2325159 |
NCBI chrNW_004936816:882...14,717
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:22321834 |
|
NCBI chrNW_004936470:20,480,844...20,485,955
Ensembl chrNW_004936470:20,480,829...20,485,965
|
|
G |
Mylk |
myosin light chain kinase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:12970723 PMID:18710790 |
|
NCBI chrNW_004936725:1,418,930...1,594,697
Ensembl chrNW_004936725:1,424,130...1,592,840
|
|
G |
Nagk |
N-acetylglucosamine kinase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:17085005 |
|
NCBI chrNW_004936491:15,183,493...15,193,069
Ensembl chrNW_004936491:15,183,804...15,192,950
|
|
G |
Ncoa1 |
nuclear receptor coactivator 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21080969 |
|
NCBI chrNW_004936493:7,368,393...7,605,754
Ensembl chrNW_004936493:7,368,462...7,465,615
|
|
G |
Ndc80 |
NDC80 kinetochore complex component |
disease_progression |
ISO |
associated with melanoma |
RGD |
PMID:31173190 |
RGD:40822820 |
NCBI chrNW_004936672:1,872,205...1,910,956
Ensembl chrNW_004936672:1,872,193...1,909,675
|
|
G |
Ndrg1 |
N-myc downstream regulated 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism|therapeutic |
CTD |
PMID:15867226 PMID:22972152 |
|
NCBI chrNW_004936470:16,051,291...16,102,563
Ensembl chrNW_004936470:16,051,015...16,102,585
|
|
G |
Nectin2 |
nectin cell adhesion molecule 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:29321541 |
|
NCBI chrNW_004936706:1,470,910...1,498,986
Ensembl chrNW_004936706:1,470,738...1,498,993
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:32682831 |
|
NCBI chrNW_004936509:6,589,967...6,621,171
Ensembl chrNW_004936509:6,590,630...6,620,262
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
|
ISO |
associated with prostate cancer |
RGD |
PMID:17974971 |
RGD:13506764 |
NCBI chrNW_004936520:733,760...850,563
Ensembl chrNW_004936520:733,668...829,435
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
|
ISO |
associated with prostate cancer;protein:increased serine phosphorylation |
RGD |
PMID:23093296 |
RGD:13506767 |
NCBI chrNW_004936494:9,537,793...9,541,187
Ensembl chrNW_004936494:9,537,008...9,541,612
|
|
G |
Nme2 |
NME/NM23 nucleoside diphosphate kinase 2 |
resistance |
ISO |
|
RGD |
PMID:8621239 |
RGD:2299081 |
NCBI chrNW_004936490:10,634,788...10,640,182
Ensembl chrNW_004936490:10,633,454...10,649,914
|
|
G |
Nos2 |
nitric oxide synthase 2 |
disease_progression |
ISO |
associated with Carcinoma, Pancreatic Ductal; protein:increased expression:pancreas associated with Gallbladder Neoplasms: protein:increased expression:gallbladder |
RGD |
PMID:12660813 PMID:14991947 PMID:15222037 |
RGD:2325242 RGD:2325250 RGD:2325254 |
NCBI chrNW_004936538:4,052,277...4,097,051
Ensembl chrNW_004936538:4,052,448...4,097,051
|
|
G |
Nos3 |
nitric oxide synthase 3 |
susceptibility |
ISO |
associated with Breast Neoplasms;DNA:polymorphism:promoter:-786T>C (human) associated with Prostatic Neoplasms;DNA:polymorphism protein:increased expression:blood vessel endothelial cell |
RGD |
PMID:12445681 PMID:14623178 PMID:14672505 |
RGD:2292080 RGD:2292081 RGD:2292087 |
NCBI chrNW_004936527:6,427,147...6,445,770
Ensembl chrNW_004936527:6,427,093...6,446,534
|
|
G |
Nppa |
natriuretic peptide A |
|
ISO |
CTD Direct Evidence: therapeutic |
CTD |
PMID:18717826 |
|
NCBI chrNW_004936474:671,362...673,610
|
|
G |
Nsun6 |
NOP2/Sun RNA methyltransferase 6 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28114269 |
|
NCBI chrNW_004936520:8,909,509...8,950,960
Ensembl chrNW_004936520:8,909,480...8,950,925
|
|
G |
Ogn |
osteoglycin |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:17085005 |
|
NCBI chrNW_004936487:2,029,755...2,043,242
Ensembl chrNW_004936487:2,028,948...2,044,387
|
|
G |
Olig2 |
oligodendrocyte transcription factor 2 |
|
ISO |
associated with breast cancer |
RGD |
PMID:27340107 |
RGD:40902824 |
NCBI chrNW_004936500:9,244,595...9,247,756
Ensembl chrNW_004936500:9,245,880...9,247,756
|
|
G |
Orai1 |
ORAI calcium release-activated calcium modulator 1 |
treatment |
ISO |
associated with stomach cancer; human cells in mouse model |
RGD |
PMID:27431311 |
RGD:152995400 |
NCBI chrNW_004936558:2,730,098...2,743,062
|
|
G |
Osm |
oncostatin M |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21937440 |
|
NCBI chrNW_004936904:390,089...394,195
|
|
G |
Pcna |
proliferating cell nuclear antigen |
|
ISO |
associated with Seminoma |
RGD |
PMID:9143022 |
RGD:2315011 |
NCBI chrNW_004936485:13,766,221...13,771,215
|
|
G |
Pde5a |
phosphodiesterase 5A |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:12972520 |
|
NCBI chrNW_004936869:24,265...117,120
Ensembl chrNW_004936869:39,122...117,127
|
|
G |
Pdgfb |
platelet derived growth factor subunit B |
|
ISO |
associated with Breast Neoplasms;mRNA, protein:increased expression:breast |
RGD |
PMID:16596190 |
RGD:2292179 |
NCBI chrNW_004936492:2,353,840...2,368,573
Ensembl chrNW_004936492:2,353,841...2,368,573
|
|
G |
Pdgfrb |
platelet derived growth factor receptor beta |
|
ISO |
associated with Carcinoma, Renal Cell mRNA,protein:increased expression: : |
RGD |
PMID:14593398 PMID:15994946 |
RGD:13703041 RGD:2292198 |
NCBI chrNW_004936504:4,762,251...4,799,789
Ensembl chrNW_004936504:4,762,184...4,799,829
|
|
G |
Pebp1 |
phosphatidylethanolamine binding protein 1 |
|
ISO |
associated with Prostatic Neoplasms;protein:decreased expression: |
RGD |
PMID:12813171 |
RGD:2302862 |
NCBI chrNW_004936668:2,316,661...2,323,015
|
|
G |
Pik3c2b |
phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 beta |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21986133 |
|
NCBI chrNW_004936567:314,957...377,544
Ensembl chrNW_004936567:314,898...378,045
|
|
G |
Pik3ca |
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha |
treatment |
ISO |
associated with colorectal cancer;DNA:mutations:: CTD Direct Evidence: marker/mechanism |
RGD CTD |
PMID:23302486 PMID:29106415 |
RGD:14402409 |
NCBI chrNW_004936566:3,924,013...3,951,052
Ensembl chrNW_004936566:3,923,934...3,951,073
|
|
G |
Pik3r3 |
phosphoinositide-3-kinase regulatory subunit 3 |
|
ISO |
associated with Adenocarcinoma, Colon |
RGD |
PMID:24837077 |
RGD:13432045 |
NCBI chrNW_004936474:27,095,125...27,171,416
Ensembl chrNW_004936474:27,095,100...27,171,252
|
|
G |
Plau |
plasminogen activator, urokinase |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:16475674 |
|
NCBI chrNW_004936521:5,238,128...5,243,829
Ensembl chrNW_004936521:5,238,093...5,243,877
|
|
G |
Plaur |
plasminogen activator, urokinase receptor |
|
ISO |
associated with Ovarian Neoplasms CTD Direct Evidence: marker/mechanism |
RGD CTD |
PMID:15659795 PMID:22577342 |
RGD:6483788 |
NCBI chrNW_004936706:840,968...855,552
|
|
G |
Plod2 |
procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 |
ameliorates |
ISO |
associated with lung non-small cell carcinoma |
RGD |
PMID:29072684 |
RGD:151665822 |
NCBI chrNW_004936519:9,053,192...9,139,221
Ensembl chrNW_004936519:9,053,033...9,140,059
|
|
G |
Pml |
PML nuclear body scaffold |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:29335545 |
|
NCBI chrNW_004936471:33,135,186...33,173,218
Ensembl chrNW_004936471:33,135,164...33,177,666
|
|
G |
Pms2 |
PMS1 homolog 2, mismatch repair system component |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:17717427 |
|
NCBI chrNW_004936750:439,396...468,747
|
|
G |
Ppia |
peptidylprolyl isomerase A |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21956400 |
|
NCBI chrNW_004936478:19,669,727...19,673,355
Ensembl chrNW_004936478:19,669,506...19,673,398
|
|
G |
Prnp |
prion protein (Kanno blood group) |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:17387271 |
|
NCBI chrNW_004936485:14,104,829...14,118,614
Ensembl chrNW_004936485:14,104,831...14,118,629
|
|
G |
Prox1 |
prospero homeobox 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:17415710 |
|
NCBI chrNW_004936628:4,185,712...4,240,680
Ensembl chrNW_004936628:4,185,706...4,238,451
|
|
G |
Prss8 |
serine protease 8 |
|
ISO |
associated with Prostatic Neoplasms;mRNA:decreased expression:prostate gland, bone |
RGD |
PMID:12518323 |
RGD:2292484 |
NCBI chrNW_004936501:13,487,863...13,491,837
Ensembl chrNW_004936501:13,485,310...13,491,905
|
|
G |
Ptch1 |
patched 1 |
|
ISO |
associated with colorectal cancer |
RGD |
PMID:20230186 |
RGD:150523835 |
NCBI chrNW_004936626:4,241,993...4,301,919
Ensembl chrNW_004936626:4,241,908...4,309,476
|
|
G |
Pten |
phosphatase and tensin homolog |
|
ISO |
CTD Direct Evidence: marker/mechanism associated with Mammary Neoplasms, Experimental |
CTD RGD |
PMID:10978354 PMID:18381417 |
RGD:2292496 |
NCBI chrNW_004936735:1,252,414...1,338,318
Ensembl chrNW_004936735:1,252,414...1,338,323
|
|
G |
Ptgis |
prostaglandin I2 synthase |
exacerbates |
ISO |
associated with colorectal cancer; protein:increased expression:colorectum (human) |
RGD |
PMID:22109564 |
RGD:151347833 |
NCBI chrNW_004936514:4,775,884...4,814,574
Ensembl chrNW_004936514:4,791,031...4,812,027
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
ISO |
CTD Direct Evidence: marker/mechanism associated with osteosarcoma; associated with lung neoplasm associated with breast neoplasm; associated with Breast Neoplasms associated with Mammary Neoplasms, Experimental |
CTD RGD |
PMID:16489006 PMID:18398660 PMID:18509974 PMID:18663571 PMID:18797196 PMID:19421193 PMID:21238650 More...
|
RGD:2300119 RGD:2300249 RGD:5135282 RGD:5135498 RGD:5135500 |
NCBI chrNW_004936481:3,821,564...3,828,086
|
|
G |
Ptk2 |
protein tyrosine kinase 2 |
|
ISO |
associated with Mammary Neoplasms, Experimental |
RGD |
PMID:15930288 PMID:16547501 |
RGD:2292557 RGD:2292560 |
NCBI chrNW_004936470:10,379,855...10,578,531
Ensembl chrNW_004936470:10,379,872...10,578,543
|
|
G |
Pxn |
paxillin |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:18492274 |
|
NCBI chrNW_004936668:660,415...709,282
|
|
G |
Rac1 |
Rac family small GTPase 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:18506888 |
|
NCBI chrNW_004936750:107,689...122,679
Ensembl chrNW_004936750:107,689...122,676
|
|
G |
Rad52 |
RAD52 homolog, DNA repair protein |
susceptibility |
ISO |
associated with colorectal cancer; DNA:SNP:3'utr: (rs7963551) (human) |
RGD |
PMID:29245274 |
RGD:151361161 |
NCBI chrNW_004936606:1,070,336...1,099,684
Ensembl chrNW_004936606:1,066,905...1,099,703
|
|
G |
Ramp2 |
receptor activity modifying protein 2 |
|
ISO |
|
RGD |
PMID:31754214 |
RGD:152985691 |
NCBI chrNW_004936490:17,479,899...17,481,788
Ensembl chrNW_004936490:17,479,650...17,482,716
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27137931 |
|
NCBI chrNW_004936565:1,596,227...1,746,706
Ensembl chrNW_004936565:1,597,593...1,746,846
|
|
G |
Reck |
reversion inducing cysteine rich protein with kazal motifs |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:17233834 |
|
NCBI chrNW_004936524:4,021,666...4,099,703
Ensembl chrNW_004936524:4,021,660...4,099,705
|
|
G |
Rhoa |
ras homolog family member A |
|
ISO |
associated with Ovarian Neoplasms |
RGD |
PMID:12808121 |
RGD:2298873 |
NCBI chrNW_004936529:1,000,050...1,045,655
Ensembl chrNW_004936529:999,935...1,045,681
|
|
G |
Rhoc |
ras homolog family member C |
|
ISO |
CTD Direct Evidence: marker/mechanism associated with Ovarian Neoplasms |
CTD RGD |
PMID:12808121 PMID:18230616 |
RGD:2298873 |
NCBI chrNW_004936690:1,255,126...1,258,288
|
|
G |
Rit1 |
Ras like without CAAX 1 |
ameliorates |
ISO |
associated with esophagus squamous cell carcinoma; human cells in mouse model |
RGD |
PMID:30348939 |
RGD:152999018 |
NCBI chrNW_004936580:5,157,351...5,166,790
Ensembl chrNW_004936580:5,156,565...5,167,040
|
|
G |
Ror1 |
receptor tyrosine kinase like orphan receptor 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:28114269 |
|
NCBI chrNW_004936692:1,327,779...1,702,350
Ensembl chrNW_004936692:1,328,195...1,699,703
|
|
G |
Rps6ka3 |
ribosomal protein S6 kinase A3 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21488662 |
|
NCBI chrNW_004936624:3,897,878...4,005,664
Ensembl chrNW_004936624:3,897,791...4,000,558
|
|
G |
Rxra |
retinoid X receptor alpha |
|
ISO |
associated with Prostatic Neoplasms |
RGD |
PMID:15318950 |
RGD:1643115 |
NCBI chrNW_004936669:2,735,111...2,763,060
Ensembl chrNW_004936669:2,738,448...2,763,070
|
|
G |
S100a4 |
S100 calcium binding protein A4 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:21636539 PMID:21685359 PMID:36008464 |
|
NCBI chrNW_004936580:3,355,751...3,358,030
Ensembl chrNW_004936580:3,355,699...3,358,242
|
|
G |
Serpinb5 |
serpin family B member 5 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:19514085 |
|
NCBI chrNW_004936497:2,067,796...2,089,965
Ensembl chrNW_004936497:2,069,035...2,089,745
|
|
G |
Serpinc1 |
serpin family C member 1 |
treatment |
ISO |
associated with Melanoma associated with Adenocarcinoma, Colon |
RGD |
PMID:16440418 |
RGD:1599327 |
NCBI chrNW_004936481:13,981,014...13,993,750
Ensembl chrNW_004936481:13,981,019...13,993,634
|
|
G |
Serpinf1 |
serpin family F member 1 |
|
ISO |
associated with Prostatic Neoplasms |
RGD |
PMID:15313905 |
RGD:2312355 |
NCBI chrNW_004936538:7,885,816...7,898,308
Ensembl chrNW_004936538:7,885,475...7,899,113
|
|
G |
Sirt1 |
sirtuin 1 |
|
ISO |
CTD Direct Evidence: marker/mechanism |
CTD |
PMID:27793039 |
|
NCBI chrNW_004936521:10,296,097...10,316,673
Ensembl chrNW_004936521:10,296,097...10,322,215
|
|
G |
Six1 |
SIX homeobox 1 |
|
ISO |
human gene in a mouse model |
RGD |
PMID:23435380 |
RGD:11561950 |
NCBI chrNW_004936495:4,839,496...4,842,906
Ensembl chrNW_004936495:4,838,051...4,842,994
|
|